



Managed Financial Conflicts of Interest (FCOIs) with Research Funded by the Public Health Service (PHS)

Current as of August 7, 2023

1.

Date Disclosed: April 22, 2013

Investigator with FCOI: William Federspiel, Ph.D.

Title: Professor of Chemical Engineering, Surgery and Bioengineering

PHS Funding: NIH 1 R01 HL117637-01 *Paracorporeal Ambulatory Assist Lung*

Role on Research Project: Co-Investigator

Name of Entity in which Significant Financial Interest (SFI) is held: ALung Technologies, Inc.

Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh; consulting; reimbursed/sponsored travel; equity interest

Approximate dollar value of the SFI: Consulting income and reimbursed/sponsored travel between \$20,000 – \$39,000; intellectual property rights and equity interest are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

2.

Date Disclosed: August 19, 2013

Investigator with FCOI: Bruce Freeman, Ph.D.

Title: Professor and Chair of Pharmacology and Chemical Biology

PHS Funding: NIH 4 R37 HL058115-17 *Redox Transduction of Nitric Oxide Signaling*

Role on Research Project: Co-Investigator

Name of Entity in which Significant Financial Interest (SFI) is held: Complexa, Inc.

Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Alabama, Birmingham and/or the University of Pittsburgh and licensed to Complexa, Inc.; equity interest

Approximate dollar value of the SFI: The interests are ones whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

3.

Date Disclosed: August 19, 2013

Investigator with FCOI: Francisco Schopfer, Ph.D.

Title: Research Associate Professor of Pharmacology and Chemical Biology

PHS Funding: NIH 4 R37 HL058115-17 *Redox Transduction of Nitric Oxide Signaling*

Role on Research Project: Co-Investigator

Name of Entity in which Significant Financial Interest (SFI) is held: Complexa, Inc.

Nature of the SFI: Consulting; equity interest; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Complexa, Inc.

Approximate dollar value of the SFI: Consulting income between \$20,000 - \$39,999; intellectual property rights and equity interest are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

4. *FCOI eliminated August 31, 2018*

Date Disclosed: July 31, 2014

Investigator with FCOI: Stephen H. Thorne, Ph.D.

Title: Assistant Professor of Cell Biology

PHS Funding: NIH 1 R01 CA178766-01A1 *Creation of Immuno-Oncolytic Viruses for Cancer Therapy*

Role on Research Project: Co-Investigator

Name of Entity in which Significant Financial Interest (SFI) is held: Western Oncolytics

Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Western Oncolytics; equity interest

Approximate dollar value of the SFI: The interests are ones whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

5.

Date Disclosed: February 17, 2015

Investigator with FCOI: Lee M. Ritterband, Ph.D.

Title: Professor of Psychiatry and Neurobehavioral Sciences, University of Virginia

PHS Funding: NIH 4 UH 3HL125103-01 *Pragmatic Trial of Behavioral Interventions for Insomnia in Hypertensive Patients*

Role on Research Project: Principal Investigator

Name of Entity in which Significant Financial Interest (SFI) is held: BeHealth Solutions, LLC

Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Virginia and licensed to BeHealth Solutions, LLC; equity interest

Approximate dollar value of the SFI: The interests are ones whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

6.

Date Disclosed: March 20, 2015

Investigator with FCOI: Mark H. Yazer, M.D.

Title: Professor of Pathology

PHS Funding: NIH HHSN 268201100004 *Recipient Epidemiology and Donor Evaluation Study-III (REDS-III)*

Role on Research Project: Principal Investigator

Name of Entity in which Significant Financial Interest (SFI) is held: Octapharma

Nature of the SFI: Consulting

Approximate dollar value of the SFI: \$5,000 – \$9,999

7.

Date Disclosed: April 30, 2015

Investigator with FCOI: Louis D. Faló, Jr., M.D., Ph.D.

Title: Professor and Chair of Dermatology

PHS Funding: 5 P50 CA121973-07 (Sub-project ID: 7388) *SPORE in Skin Cancer*

Role on Research Project: Principal Investigator of bench and animal, and Co-Investigator of human subject, research

Name of Entity in which Significant Financial Interest (SFI) is held: SkinJect

Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to SkinJect; equity interest

Approximate dollar value of the SFI: The interests are ones whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

8.

Date Disclosed: May 14, 2015

Investigator with FCOI: Saul Shiffman, Ph.D.

Title: Professor of Psychology

PHS Funding: NIH 5 R01 DA034629-02 *Cessation in Non-Daily Smokers: a RCT of NRT with Ecological Momentary Assessment*

Role on Research Project: Co-Investigator

Name of Entity in which Significant Financial Interest (SFI) is held: Reynolds American, Inc.; Nicovum (a subsidiary of Reynolds American, Inc.); JSR, LLC

Nature of the SFI: Consulting with Reynolds American and Nicovum; reimbursed/sponsored travel from Reynolds American; intellectual property rights (e.g., royalties, patents, copyrights) assigned to JSR; equity interest in JSR

Approximate dollar value of the SFI: Consulting income between \$500,000 - \$549,999; reimbursed/sponsored travel between \$20,000 - \$39,999; intellectual property rights and equity interest are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

9. *FCOI eliminated June 7, 2019*

Date Disclosed: May 28, 2015

Investigator with FCOI: Dario Vitturi, Ph.D.

Title: Research Instructor, Department of Pharmacology & Chemical Biology

PHS Funding: NIH R37 HL058115 *Redox transduction of nitric oxide signaling*

Role on Research Project: Co-Investigator

Name of Entity in which Significant Financial Interest (SFI) is held: Complexa, Inc.

Nature of the SFI: Consulting

Approximate dollar value of the SFI: \$10,000 - \$19,999

10. *FCOI eliminated June 13, 2019*

Date Disclosed: August 11, 2015

Investigator with FCOI: Stacy Gelhaus Wendell, Ph.D.

Title: Research Assistant Professor of Pharmacology & Chemical Biology

PHS Funding: NIH R37 HL058115 *Redox transduction of nitric oxide signaling*

Role on Research Project: Co-Investigator

Name of Entity in which Significant Financial Interest (SFI) is held: Complexa, Inc.

Nature of the SFI: Consulting

Approximate dollar value of the SFI: \$10,000 - \$19,999

11.

Date Disclosed: August 13, 2015

Investigator with FCOI: Francisco Schopfer, Ph.D.

Title: Research Associate Professor of Pharmacology and Chemical Biology

PHS Funding: NIH 1 R01 AR066548-01A1 *The Immunoregulatory Effects of Electrophilic Fatty acids on Psoriasis*

Role on Research Project: Co-Investigator

Name of Entity in which Significant Financial Interest (SFI) is held: Complexa, Inc.

Nature of the SFI: Consulting; equity interest; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Complexa, Inc.

Approximate dollar value of the SFI: Consulting income between \$20,000 - \$39,999; intellectual property rights and equity interest are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

12. *FCOI eliminated April 12, 2019*

Date Disclosed: August 18, 2015

Investigator with FCOI: Mark Gladwin, M.D.

Title: Professor and Chair of Medicine

PHS Funding: NIH 1 K23 HL124051-01A1 *Nitrite Modulation of Hypertension, Platelet Activation and Mitochondrial Function*

Role on Research Project: Co-Investigator

Name of Entity in which Significant Financial Interest (SFI) is held: National Institutes of Health

Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the National Institutes of Health and licensed to Mast Therapeutics

Approximate dollar value of the SFI: \$1 - \$4,999

13. *FCOI eliminated August 25, 2016*

Date Disclosed: February 3, 2016

Investigator with FCOI: Fuchiang (Rich) Tsui, Ph.D.

Title: Research Assistant Professor of Biomedical Informatics

PHS Funding: NIH 5 TL1 TR000145-10 *University of Pittsburgh Clinical and Translational Science Institute*

Role on Research Project: Principal Investigator

Name of Entity in which Significant Financial Interest (SFI) is held: University of Pittsburgh

Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Vervtality

Approximate dollar value of the SFI: The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

14. *FCOI eliminated April 26, 2017*

Date Disclosed: February 8, 2016

Investigator with FCOI: James Eles

Title: Graduate Student, Department of Bioengineering

PHS Funding: NIH R01 NS062019 *Biomimetic Surfaces for Neural Implants*

Role on Research Project: Co-Investigator

Name of Entity in which Significant Financial Interest (SFI) is held: University of Pittsburgh

Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Interphase Materials

Approximate dollar value of the SFI: The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

15. *FCOI eliminated April 26, 2017*

Date Disclosed: February 8, 2016

Investigator with FCOI: Xinyan (Tracy) Cui

Title: Professor of Bioengineering

PHS Funding: NIH R01 NS062019 *Biomimetic Surfaces for Neural Implants*

Role on Research Project: Principal Investigator

Name of Entity in which Significant Financial Interest (SFI) is held: University of Pittsburgh

Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Interphase Materials

Approximate dollar value of the SFI: The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

16. *FCOI eliminated July 14, 2017*

Date Disclosed: February 12, 2016

Investigator with FCOI: Edward Prochownik, M.D., Ph.D.

Title: Professor of Pediatrics and Microbiology & Molecular Genetics

PHS Funding: NIH 1 U54 CA199092-01 *Center for Multiple Myeloma Nanotherapy*

Role on Research Project: Principal Investigator

Name of Entity in which Significant Financial Interest (SFI) is held: University of Pittsburgh

Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh

Approximate dollar value of the SFI: The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

17.

Date Disclosed: February 22, 2016

Investigator with FCOI: Andrew Hinck, Ph.D.

Title: Visiting Professor of Structural Biology

PHS Funding: NIH R01 CA172886 *Inhibition of the Tumor-Promoting Effects of TGF-Beta in Advanced Prostate Cancer*

Role on Research Project: Principal Investigator

Name of Entity in which Significant Financial Interest (SFI) is held: University of Texas Health Science Center at San Antonio

Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Texas Health Science Center at San Antonio

Approximate dollar value of the SFI: The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

18. *FCOI eliminated August 8, 2018*

Date Disclosed: April 25, 2016

Investigator with FCOI: Rebecca Jacobson, M.D., M.S.

Title: Professor of Biomedical Informatics and Pathology

PHS Funding: NIH U24 CA180921 *Advanced Development of TIES-Enhancing Access to Tissue for Cancer Research*

Role on Research Project: Principal Investigator

Name of Entity in which Significant Financial Interest (SFI) is held: NEXI

Nature of the SFI: Consulting; equity interest; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to NEXI

Approximate dollar value of the SFI: The interests are ones whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

19. *FCOI eliminated August 8, 2018*

Date Disclosed: April 25, 2016

Investigator with FCOI: Girish Chavan

Title: Staff, Department of Biomedical Informatics

PHS Funding: NIH U24 CA180921 *Advanced Development of TIES-Enhancing Access to Tissue for Cancer Research*

Role on Research Project: Co-Investigator

Name of Entity in which Significant Financial Interest (SFI) is held: NEXI

Nature of the SFI: Equity interest; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to NEXI

Approximate dollar value of the SFI: The interests are ones whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

20. *FCOI eliminated August 8, 2018*

Date Disclosed: April 25, 2016

Investigator with FCOI: Eugene Tseytlin

Title: Staff, Department of Biomedical Informatics

PHS Funding: NIH U24 CA180921 *Advanced Development of TIES-Enhancing Access to Tissue for Cancer Research*

Role on Research Project: Co-Investigator

Name of Entity in which Significant Financial Interest (SFI) is held: NEXI

Nature of the SFI: Consulting; equity interest; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to NEXI

Approximate dollar value of the SFI: The interests are ones whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

21. *FCOI eliminated June 7, 2019*

Date Disclosed: May 16, 2016

Investigator with FCOI: Dario Vitturi, Ph.D.

Title: Research Instructor, Department of Pharmacology & Chemical Biology

PHS Funding: NIH U01 HL117721 *Cellular and Molecular Mechanisms of Acute Lung Injury in Sickle Cell Disease*

Role on Research Project: Co-Investigator

Name of Entity in which Significant Financial Interest (SFI) is held: Complexa, Inc.

Nature of the SFI: Consulting

Approximate dollar value of the SFI: \$10,000 - \$19,999

22.

Date Disclosed: June 9, 2016

Investigator with FCOI: Joseph Glorioso, Ph.D.

Title: Professor, Department of Microbiology & Molecular Genetics

PHS Funding: NIH P01 CA163205 (Sub-project ID: 7345) *Circumventing Barriers to Effective Oncolytic Virotherapy of Malignant Gliomas*

Role on Research Project: Principal Investigator of bench research and Co-Investigator of animal research

Name of Entity in which Significant Financial Interest (SFI) is held: Oncorus

Nature of the SFI: Consulting; equity interest; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Oncorus

Approximate dollar value of the SFI: Consulting income between \$100,000 - \$149,999; equity interest between \$450,000 - \$499,999; intellectual property rights is an interest whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

23.

Date Disclosed: June 9, 2016

Investigator with FCOI: Paola Grandi, Ph.D.

Title: Assistant Professor, Department of Neurological Surgery

PHS Funding: NIH P01 CA163205 (Sub-project ID: 7345) *Circumventing Barriers to Effective Oncolytic Virotherapy of Malignant Gliomas*

Role on Research Project: Co-Investigator

Name of Entity in which Significant Financial Interest (SFI) is held: Oncorus

Nature of the SFI: Consulting; equity interest; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Oncorus

Approximate dollar value of the SFI: Consulting income between \$100,000 - \$149,999; intellectual property rights and equity interest are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

24.

Date Disclosed: June 9, 2016

Investigator with FCOI: Justus Cohen, Ph.D.

Title: Research Instructor, Department of Microbiology & Molecular Genetics

PHS Funding: NIH P01 CA163205 (Sub-project ID: 7345) *Circumventing Barriers to Effective Oncolytic Virotherapy of Malignant Gliomas*

Role on Research Project: Co-Investigator

Name of Entity in which Significant Financial Interest (SFI) is held: University of Pittsburgh

Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Oncorus

Approximate dollar value of the SFI: The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

25.

Date Disclosed: June 9, 2016

Investigator with FCOI: William Goins, Ph.D.

Title: Research Assistant Professor, Department of Microbiology & Molecular Genetics

PHS Funding: NIH P01 CA163205 (Sub-project ID: 7345) *Circumventing Barriers to Effective Oncolytic Virotherapy of Malignant Gliomas*

Role on Research Project: Principal Investigator and Co-Investigator

Name of Entity in which Significant Financial Interest (SFI) is held: Oncorus

Nature of the SFI: Consulting; equity interest

Approximate dollar value of the SFI: Consulting income between \$5,000 - \$9,999; equity interest between \$5,000 - \$9,999.

26.

Date Disclosed: June 9, 2016

Investigator with FCOI: Nduka Amankulor, M.D.

Title: Assistant Professor, Department of Neurological Surgery

PHS Funding: NIH P01 CA163205 (Sub-project ID: 7345) *Circumventing Barriers to Effective Oncolytic Virotherapy of Malignant Gliomas*

Role on Research Project: Principal Investigator

Name of Entity in which Significant Financial Interest (SFI) is held: Oncorus

Nature of the SFI: Consulting; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Oncorus

Approximate dollar value of the SFI: Consulting income between \$5,000 - \$9,999; intellectual property rights is an interest whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

27. *FCOI eliminated November 30, 2018*

Date Disclosed: June 13, 2016

Investigator with FCOI: Paola Grandi, Ph.D.

Title: Assistant Professor, Department of Neurological Surgery

PHS Funding: NIH R01 CA175052 *Enhanced GBM Therapy Using a New Class of HSV Oncolytic Vector*

Role on Research Project: Principal Investigator

Name of Entity in which Significant Financial Interest (SFI) is held: Oncorus

Nature of the SFI: Consulting; equity interest; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Oncorus

Approximate dollar value of the SFI: Consulting income between \$100,000 - \$149,999; intellectual property rights and equity interest are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

28.

Date Disclosed: June 13, 2016

Investigator with FCOI: William Goins, Ph.D.

Title: Research Assistant Professor, Department of Microbiology & Molecular Genetics

PHS Funding: NIH R01 CA175052 *Enhanced GBM Therapy Using a New Class of HSV Oncolytic Vector*

Role on Research Project: Co-Investigator

Name of Entity in which Significant Financial Interest (SFI) is held: Oncorus

Nature of the SFI: Consulting; equity interest

Approximate dollar value of the SFI: Consulting income between \$5,000 - \$9,999; equity interest between \$5,000 - \$9,999.

29.

Date Disclosed: June 13, 2016

Investigator with FCOI: Nduka Amankulor, M.D.

Title: Assistant Professor, Department of Neurological Surgery

PHS Funding: NIH R01 CA175052 *Enhanced GBM Therapy Using a New Class of HSV Oncolytic Vector*

Role on Research Project: Principal Investigator

Name of Entity in which Significant Financial Interest (SFI) is held: Oncorus

Nature of the SFI: Consulting; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Oncorus

Approximate dollar value of the SFI: Consulting income between \$5,000 - \$9,999; intellectual property rights is an interest whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

30. *FCOI eliminated October 3, 2016*

Date Disclosed: June 28, 2016

Investigator with FCOI: Michael McClincy, M.D.

Title: Fellow, Massachusetts General Hospital

PHS Funding: NIH 5 TL1 TR000145-10 *University of Pittsburgh Clinical and Translational Science Institute*

Role on Research Project: Co-Investigator

Name of Entity in which Significant Financial Interest (SFI) is held: University of Pittsburgh

Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Impellia

Approximate dollar value of the SFI: The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

31.

Date Disclosed: June 28, 2016

Investigator with FCOI: Kevin Bell, Ph.D.

Title: Research Assistant Professor, Department of Orthopaedic Surgery

PHS Funding: NIH 5 TL1 TR000145-10 *University of Pittsburgh Clinical and Translational Science Institute*

Role on Research Project: Co-Investigator

Name of Entity in which Significant Financial Interest (SFI) is held: University of Pittsburgh

Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Impellia

Approximate dollar value of the SFI: The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

32. *FCOI eliminated August 25, 2016*

Date Disclosed: June 28, 2016

Investigator with FCOI: Robert Hartman, Ph.D.

Title: Postdoctoral Associate, Department of Physical Medicine & Rehabilitation

PHS Funding: NIH 5 TL1 TR000145-10 *University of Pittsburgh Clinical and Translational Science Institute*

Role on Research Project: Co-Investigator

Name of Entity in which Significant Financial Interest (SFI) is held: University of Pittsburgh

Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Impellia

Approximate dollar value of the SFI: The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

33. *FCOI eliminated September 2, 2016*

Date Disclosed: June 28, 2016

Investigator with FCOI: Xinyan (Tracy) Cui

Title: Professor of Bioengineering

PHS Funding: NIH 5 TL1 TR000145-10 *University of Pittsburgh Clinical and Translational Science Institute*

Role on Research Project: Co-Investigator

Name of Entity in which Significant Financial Interest (SFI) is held: University of Pittsburgh

Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Interphase Materials

Approximate dollar value of the SFI: The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

34. *FCOI eliminated September 2, 2016*

Date Disclosed: June 28, 2016

Investigator with FCOI: James Eles

Title: Graduate Student, Department of Bioengineering

PHS Funding: NIH 5 TL1 TR000145-10 *University of Pittsburgh Clinical and Translational Science Institute*

Role on Research Project: Co-Investigator

Name of Entity in which Significant Financial Interest (SFI) is held: University of Pittsburgh

Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Interphase Materials

Approximate dollar value of the SFI: The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

35. *FCOI eliminated July 19, 2017*

Date Disclosed: July 1, 2016

Investigator with FCOI: Joel S. Greenberger, M.D.

Title: Professor and Chair of Radiation Oncology

PHS Funding: NIH 2 U19 AI068021-11 *Signature-Directed, Sequential Delivery of Radiation Mitigators*

Role on Research Project: Principal Investigator

Name of Entity in which Significant Financial Interest (SFI) is held: University of Pittsburgh

Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh

Approximate dollar value of the SFI: The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

36. *FCOI eliminated July 19, 2017*

Date Disclosed: July 1, 2016

Investigator with FCOI: Michael W. Epperly, Ph.D.

Title: Associate Professor of Radiation Oncology

PHS Funding: NIH 2 U19 AI068021-11 *Signature-Directed, Sequential Delivery of Radiation Mitigators*

Role on Research Project: Principal Investigator

Name of Entity in which Significant Financial Interest (SFI) is held: University of Pittsburgh

Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh

Approximate dollar value of the SFI: The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

37. *FCOI eliminated August 4, 2017*

Date Disclosed: July 5, 2016

Investigator with FCOI: Shivalingappa Swamynathan, Ph.D.

Title: Associate Professor of Ophthalmology and Cell Biology

PHS Funding: NIH 5 R01 EY022898-03 *Corneal Expression and Function of Slurp1*

Role on Research Project: Principal Investigator

Name of Entity in which Significant Financial Interest (SFI) is held: University of Pittsburgh

Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh

Approximate dollar value of the SFI: The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

38. *FCOI eliminated August 4, 2017*

Date Disclosed: July 5, 2016

Investigator with FCOI: Sudha Swamynathan

Title: Research Technician, Department of Ophthalmology

PHS Funding: NIH 5 R01 EY022898-03 *Corneal Expression and Function of Slurp1*

Role on Research Project: Co-Investigator

Name of Entity in which Significant Financial Interest (SFI) is held: University of Pittsburgh

Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh

Approximate dollar value of the SFI: The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

39. *FCOI eliminated July 6, 2020*

Date Disclosed: July 13, 2016

Investigator with FCOI: Yuri Nikiforov, M.D., Ph.D.

Title: Professor of Pathology

PHS Funding: NIH 2 P50 CA097190-11 *Head and Neck Cancer SPORC*

Role on Research Project: Co-Investigator

Name of Entity in which Significant Financial Interest (SFI) is held: University of Pittsburgh

Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to UPMC

Approximate dollar value of the SFI: \$100,000-\$149,999

40.

Date Disclosed: July 14, 2016

Investigator with FCOI: Bruce Freeman, Ph.D.

Title: Professor and Chair of Pharmacology and Chemical Biology

PHS Funding: NIH 1 R21 AI122071-01A1 *The Effects of Nitrate/Nitrite and Conjugated Linoleic Acid Supplementation on the Obese Asthmatic Pathology*

Role on Research Project: Co-Investigator

Name of Entity in which Significant Financial Interest (SFI) is held: Complexa, Inc.

Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Alabama, Birmingham and/or the University of Pittsburgh and licensed to Complexa, Inc.; equity interest

Approximate dollar value of the SFI: The interests are ones whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

41. *FCOI eliminated June 13, 2019*

Date Disclosed: July 14, 2016

Investigator with FCOI: Stacy Gelhaus Wendell, Ph.D.

Title: Research Assistant Professor of Pharmacology & Chemical Biology

PHS Funding: NIH 1 R21 AI122071-01A1 *The Effects of Nitrate/Nitrite and Conjugated Linoleic Acid Supplementation on the Obese Asthmatic Pathology*

Role on Research Project: Principal Investigator of bench, and Co-Investigator on human subject, research

Name of Entity in which Significant Financial Interest (SFI) is held: Complexa, Inc.

Nature of the SFI: Consulting

Approximate dollar value of the SFI: \$10,000 - \$19,999

42. *FCOI eliminated May 4, 2020*

Date Disclosed: August 9, 2016

Investigator with FCOI: Dario A. Vignali, Ph.D.

Title: Professor and Vice Chair of Immunology

PHS Funding: NIH 9 R01 CA203689-07A1 *Interleukin-35 and the Tumor Microenvironment*

Role on Research Project: Principal Investigator of bench, and Co-Investigator on non-bench, research

Name of Entity in which Significant Financial Interest (SFI) is held: Tizona Therapeutics

Nature of the SFI: Consulting; equity interest; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the St. Jude Children's Research Hospital and licensed to Tizona Therapeutics;

Approximate dollar value of the SFI: Consulting income between \$60,000 - \$79,999; licensing proceeds from intellectual property rights between \$10,000 - \$19,999; equity interest is SFI whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

43. *FCOI eliminated July 14, 2021*

Date Disclosed: August 23, 2016

Investigator with FCOI: Bruce Freeman, Ph.D.

Title: Professor and Chair of Pharmacology and Chemical Biology

PHS Funding: NIH 1 K01 HL133331-01 *Protection against sickle cell disease nephropathy by nitrated fatty acids*

Role on Research Project: Primary Mentor

Name of Entity in which Significant Financial Interest (SFI) is held: Complexa, Inc.

Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Alabama, Birmingham and/or the University of Pittsburgh and licensed to Complexa, Inc.; equity interest

Approximate dollar value of the SFI: The interests are ones whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

44. *FCOI eliminated June 7, 2019*

Date Disclosed: August 23, 2016

Investigator with FCOI: Dario Vitturi, Ph.D.

Title: Research Instructor, Department of Pharmacology & Chemical Biology

PHS Funding: NIH 1 K01 HL133331-01 *Protection against sickle cell disease nephropathy by nitrated fatty acids*

Role on Research Project: Principal Investigator

Name of Entity in which Significant Financial Interest (SFI) is held: Complexa, Inc.

Nature of the SFI: Consulting

Approximate dollar value of the SFI: \$10,000 - \$19,999

45. *FCOI eliminated July 14, 2021*

Date Disclosed: August 23, 2016

Investigator with FCOI: Francisco Schopfer, Ph.D.

Title: Research Associate Professor of Pharmacology and Chemical Biology

PHS Funding: NIH 1 K01 HL133331-01 *Protection against sickle cell disease nephropathy by nitrated fatty acids*

Role on Research Project: Co-Investigator

Name of Entity in which Significant Financial Interest (SFI) is held: Complexa, Inc.

Nature of the SFI: Consulting; equity interest; Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Alabama, Birmingham and/or the University of Pittsburgh and licensed to Complexa, Inc.

Approximate dollar value of the SFI: Consulting income between \$20,000 - \$39,999; intellectual property rights and equity interest are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

46. *FCOI eliminated June 13, 2019*

Date Disclosed: September 1, 2016

Investigator with FCOI: Stacy Gelhaus Wendell, Ph.D.

Title: Research Assistant Professor of Pharmacology & Chemical Biology

PHS Funding: NIH 1 R01 HL132550-01 *Anti-inflammatory Lipid Mediators in Asthma*

Role on Research Project: Co-Investigator

Name of Entity in which Significant Financial Interest (SFI) is held: Complexa, Inc.

Nature of the SFI: Consulting

Approximate dollar value of the SFI: \$10,000 - \$19,999

47.

Date Disclosed: September 1, 2016

Investigator with FCOI: Bruce Freeman, Ph.D.

Title: Professor and Chair of Pharmacology and Chemical Biology

PHS Funding: NIH 1 R01 HL132550-01 *Anti-inflammatory Lipid Mediators in Asthma*

Role on Research Project: Principal Investigator

Name of Entity in which Significant Financial Interest (SFI) is held: Complexa, Inc.

Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Alabama, Birmingham and/or the University of Pittsburgh and licensed to Complexa, Inc.; equity interest

Approximate dollar value of the SFI: The interests are ones whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

48. *FCOI eliminated April 27, 2018*

Date Disclosed: September 1, 2016

Investigator with FCOI: Steven Woodcock, Ph.D.

Title: Research Instructor, Department of Pharmacology & Chemical Biology

PHS Funding: NIH 1 R01 HL132550-01 *Anti-inflammatory Lipid Mediators in Asthma*

Role on Research Project: Co-Investigator

Name of Entity in which Significant Financial Interest (SFI) is held: Complexa, Inc.

Nature of the SFI: Consulting

Approximate dollar value of the SFI: \$10,000 - \$19,999

49. *FCOI eliminated April 12, 2019*

Date Disclosed: September 19, 2016

Investigator with FCOI: Mark Gladwin, M.D.

Title: Professor and Chair of Medicine

PHS Funding: NIH 2 P01 HL103455-06 *Therapeutic Targeting of Vascular Subphenotypes of Lung Disease*

Role on Research Project: Co-Investigator

Name of Entity in which Significant Financial Interest (SFI) is held: National Institutes of Health

Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the National Institutes of Health and licensed to MAST Therapeutics

Approximate dollar value of the SFI: \$5,000 - \$9,999

50. *FCOI eliminated May 25, 2021*

Date Disclosed: September 19, 2016

Investigator with FCOI: Bruce Freeman, Ph.D.

Title: Professor and Chair of Pharmacology and Chemical Biology

PHS Funding: NIH 2 P01 HL103455-06 *Therapeutic Targeting of Vascular Subphenotypes of Lung Disease*

Role on Research Project: Principal Investigator of bench research and Co-Investigator of human subject research

Name of Entity in which Significant Financial Interest (SFI) is held: Complexa, Inc.

Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Alabama, Birmingham and/or the University of Pittsburgh and licensed to Complexa, Inc.; equity interest

Approximate dollar value of the SFI: The interests are ones whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

51. *FCOI eliminated June 13, 2019*

Date Disclosed: September 19, 2016

Investigator with FCOI: Stacy Gelhaus Wendell, Ph.D.

Title: Research Assistant Professor of Pharmacology & Chemical Biology

PHS Funding: NIH 2 P01 HL103455-06 *Therapeutic Targeting of Vascular Subphenotypes of Lung Disease*

Role on Research Project: Co-Investigator

Name of Entity in which Significant Financial Interest (SFI) is held: Complexa, Inc.

Nature of the SFI: Consulting

Approximate dollar value of the SFI: \$10,000 - \$19,999

52. *FCOI eliminated April 27, 2018*

Date Disclosed: September 19, 2016

Investigator with FCOI: Steven Woodcock, Ph.D.

Title: Research Instructor, Department of Pharmacology & Chemical Biology

PHS Funding: NIH 2 P01 HL103455-06 *Therapeutic Targeting of Vascular Subphenotypes of Lung Disease*

Role on Research Project: Co-Investigator

Name of Entity in which Significant Financial Interest (SFI) is held: Complexa, Inc.

Nature of the SFI: Consulting

Approximate dollar value of the SFI: \$10,000 - \$19,999

53. *FCOI eliminated March 20, 2018*

Date Disclosed: September 23, 2016

Investigator with FCOI: Matthew Neal, M.D.

Title: Assistant Professor of Surgery and Critical Care Medicine

PHS Funding: NIH 1 R35 GM119526-01 *Mechanistic Elucidation and Targeted Therapy of Platelet Dysfunction After Trauma*

Role on Research Project: Principal Investigator

Name of Entity in which Significant Financial Interest (SFI) is held: University of Pittsburgh

Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh

Approximate dollar value of the SFI: The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

54. *FCOI eliminated March 29, 2017*

Date Disclosed: September 23, 2016

Investigator with FCOI: Brian Suffoletto, M.D.

Title: Assistant Professor of Emergency Medicine

PHS Funding: NIH 1 R01 AA23650-01A1 *Mechanisms of Change for an Effective Alcohol Text Message Intervention*

Role on Research Project: Principal Investigator

Name of Entity in which Significant Financial Interest (SFI) is held: University of Pittsburgh

Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to healthStratica

Approximate dollar value of the SFI: The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

55.

Date Disclosed: September 27, 2016

Investigator with FCOI: Patricia Opresko, Ph.D.

Title: Associate Professor of Environmental and Occupational Health

PHS Funding: NIH 2 R44 GM108187-03 *GammaPNA Miniprobos for Telomere Analysis and RNA FISH*

Role on Research Project: Principal Investigator

Name of Entity in which Significant Financial Interest (SFI) is held: University of Pittsburgh

Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to PNA Innovations, Inc.

Approximate dollar value of the SFI: The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

56. *FCOI eliminated June 13, 2019*

Date Disclosed: October 5, 2016

Investigator with FCOI: Stacy Gelhaus Wendell, Ph.D.

Title: Research Assistant Professor of Pharmacology & Chemical Biology
PHS Funding: NIH 1 U54 DK112079-01 *University of Pittsburgh O'Brien Cooperative Research Center Program*
Role on Research Project: Co-Investigator
Name of Entity in which Significant Financial Interest (SFI) is held: Complexa, Inc.
Nature of the SFI: Consulting
Approximate dollar value of the SFI: \$10,000 - \$19,999

57.

Date Disclosed: October 10, 2016
Investigator with FCOI: Guergana Savova, Ph.D.
Title: Associate Professor of Pediatrics, Harvard Medical School and Computational Health Informatics Program at Boston Children's Hospital
PHS Funding: NIH 5 U24 CA184407-03 *Cancer Deep Phenotype Extraction from Electronic Medical Records*
Role on Research Project: Principal Investigator
Name of Entity in which Significant Financial Interest (SFI) is held: Wired Informatics, LLC
Nature of the SFI: Equity interest
Approximate dollar value of the SFI: The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

58. *FCOI eliminated June 17, 2021*

Date Disclosed: October 18, 2016
Investigator with FCOI: John Kellum, M.D.
Title: Professor and Vice Chair for Research, Department of Critical Care Medicine
PHS Funding: NIH 1 R01 DK106256-01A1 *Biomarker Effectiveness Analysis in Contrast Nephropathy (BEACON)*
Role on Research Project: Co-Investigator
Name of Entity in which Significant Financial Interest (SFI) is held: bioMérieux and Astute Medical (a subsidiary of bioMérieux)
Nature of the SFI: Consulting
Approximate dollar value of the SFI: \$20,000 - \$39,999

59. *FCOI eliminated July 19, 2017*

Date Disclosed: October 25, 2016
Investigator with FCOI: Alexander Deiters, Ph.D.
Title: Professor of Chemistry
PHS Funding: NIH 1 R21 HD 85206-01A1 *Optical Control of Translation and Gene Editing in Zebrafish Embryos*
Role on Research Project: Principal Investigator
Name of Entity in which Significant Financial Interest (SFI) is held: North Carolina State University

Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to North Carolina State University

Approximate dollar value of the SFI: The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

60.

Date Disclosed: October 26, 2016

Investigator with FCOI: Bonnie Hall, Ph.D.

Title: Research Instructor, Department of Microbiology & Molecular Genetics

PHS Funding: NIH P01 CA163205 (Sub-project ID: 7345) *Circumventing Barriers to Effective Oncolytic Virotherapy of Malignant Gliomas*

Role on Research Project: Co-Investigator

Name of Entity in which Significant Financial Interest (SFI) is held: Oncorus

Nature of the SFI: Consulting

Approximate dollar value of the SFI: \$10,000 - \$19,999

61. *FCOI eliminated April 30, 2018*

Date Disclosed: November 2, 2016

Investigator with FCOI: Mary Loghmani, P.T., Ph.D.

Title: Associate Professor of Physical Therapy, Indiana University

PHS Funding: NIH 5 P2C HD086843-02 *Alliance for Regenerative Rehabilitation Research & Training (AR3T)*

Role on Research Project: Principal Investigator

Name of Entity in which Significant Financial Interest (SFI) is held: Health Smart Technologies, Inc.

Nature of the SFI: Equity interest

Approximate dollar value of the SFI: The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

62. *FCOI eliminated March 3, 2018*

Date Disclosed: November 17, 2016

Investigator with FCOI: Maliha Zahid, M.D., Ph.D.

Title: Research Instructor, Department of Developmental Biology

PHS Funding: NIH 1 UL1 TR 001857-01 *University of Pittsburgh Clinical and Translational Science Institute*

Role on Research Project: Principal Investigator

Name of Entity in which Significant Financial Interest (SFI) is held: University of Pittsburgh

Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh

Approximate dollar value of the SFI: The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

63.

Date Disclosed: January 4, 2017

Investigator with FCOI: Lee M. Ritterband, Ph.D.

Title: Professor of Psychiatry and Neurobehavioral Sciences, University of Virginia

PHS Funding: NIH 1 R03 HL135213-01 *Feasibility and Acceptability of an internet-based cognitive-behavioral treatment for insomnia in adults with asthma*

Role on Research Project: Consultant

Name of Entity in which Significant Financial Interest (SFI) is held: BeHealth Solutions, LLC

Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Virginia and licensed to BeHealth Solutions, LLC; equity interest

Approximate dollar value of the SFI: The interests are ones whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

64.

Date Disclosed: January 17, 2017

Investigator with FCOI: Yadong Wang, Ph.D.

Title: Professor, Department of Bioengineering

PHS Funding: NIH 7 R21 EB016774-03 *Biomimetic Coacervate Delivery of Muscle Stem Cell to Improve Cardiac Repair*

Role on Research Project: Principal Investigator

Name of Entity in which Significant Financial Interest (SFI) is held: University of Pittsburgh

Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh

Approximate dollar value of the SFI: The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

65.

Date Disclosed: March 2, 2017

Investigator with FCOI: Kenneth W. Kinzler, PhD

Title: Professor of Oncology, Johns Hopkins University

PHS Funding: NIH 2 U01 CA152753-06 *ctDNA for the Early Detection and Monitoring of Colorectal Cancer*

Role on Research Project: Principal Investigator

Name of the Entity in which Significant Financial Interest (SFI) is held: Sysmex Corporation

Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to Johns Hopkins University and licensed to Sysmex Corporation; payment for services

Approximate dollar value of the SFI: Intellectual property royalty distributions between \$60,000 - \$79,999; payment for services between \$60,000-\$79,999

66.

Date Disclosed: June 21, 2017

Investigator with FCOI: Joseph Glorioso, PhD

Title: Professor of Microbiology & Molecular Genetics

PHS Funding: NIH 5 R01 CA175052-04 *Enhanced GBM Therapy Using a New Class of HSV Oncolytic Vector*

Role on Research Project: Principal Investigator

Name of the Entity in which Significant Financial Interest (SFI) is held: Oncorus

Nature of the SFI: Consulting; equity interest; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Oncorus

Approximate dollar value of the SFI: Consulting income between \$100,000 - \$149,999; equity interest between \$450,000 - \$499,999; intellectual property rights is an interest whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

67.

Date Disclosed: July 26, 2017

Investigator with FCOI: Beibei Bill Chen, PhD

Title: Associate Professor of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine

PHS Funding: NIH 5 UH3 HL123502 *A New Genus of Ubiquitin-Based Anti-Inflammatories for COPD*

Role on Research Project: Co-Investigator

Name of the Entity in which Significant Financial Interest (SFI) is held: Koutif Therapeutics

Nature of the SFI: equity interest; consulting; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Koutif Therapeutics

Approximate dollar value of the SFI: Consulting income between \$20,000 - \$39,999; intellectual property rights and equity interests are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

68.

Date Disclosed: July 26, 2017

Investigator with FCOI: Rama K. Mallampalli, MD

Title: Division Chief, Division of Pulmonary, Allergy, and Critical Care Medicine

PHS Funding: NIH 5 UH3 HL123502 *A New Genus of Ubiquitin-Based Anti-Inflammatories for COPD*

Role on Research Project: Principal Investigator of bench, and Co-Investigator of animal, research

Name of the Entity in which Significant Financial Interest (SFI) is held: Koutif Therapeutics

Nature of the SFI: equity interest; consulting; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Koutif Therapeutics

Approximate dollar value of the SFI: Consulting income between \$20,000 - \$39,999; intellectual property rights and equity interest are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

69.

Date Disclosed: July 26, 2017

Investigator with FCOI: Xiang-Qun (Sean) Xie, PhD, EMBA

Title: Associate Dean for Research Innovation and Professor, Department of Pharmaceutical Sciences

PHS Funding: NIH 1 R44 CA210882 *SQSTM1/P62-Targeted Small Molecules for Multiple Myeloma Disease*

Role on Research Project: Co-Investigator

Name of the Entity in which Significant Financial Interest (SFI) is held: ID4Pharma, LLC

Nature of the SFI: equity interest; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and optioned/licensed to ID4Pharma

Approximate dollar value of the SFI: The interests are ones whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

70.

Date Disclosed: August 9, 2017

Investigator with FCOI: John M. Kirkwood, MD

Title: Professor of Medicine, Division of Hematology/Oncology

PHS Funding: NIH 5 U01 CA180820 *ECOG-ACRIN Operations Center*

Role on Research Project: Co-Investigator

Name of the Entity in which Significant Financial Interest (SFI) is held: Novartis

Nature of the SFI: Consulting

Approximate dollar value of the SFI: \$10,000 - \$19,999

71.

Date Disclosed: October 12, 2017

Investigator with FCOI: Steven Moulton, MD

Title: Professor of Surgery, University of Colorado School of Medicine

PHS Funding: NIH 7 UM1 HL120877 *Analysis and Characterization of Trauma-Induced Coagulopathy*

Role on Research Project: Co-Investigator

Name of the Entity in which Significant Financial Interest (SFI) is held: Flashback Technologies, Inc.

Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Colorado and licensed to Flashback Technologies, Inc.; equity interest; consulting; management position

Approximate dollar value of the SFI: Consulting income between \$10,000-\$19,999; intellectual property rights between \$10,000-\$19,999; management position is unpaid; equity interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

72.

Date Disclosed: November 8, 2017

Investigator with FCOI: Francisco Schopfer, Ph.D.

Title: Research Associate Professor of Pharmacology and Chemical Biology

PHS Funding: NIH 5 R01 HL132550 *Anti-Inflammatory Lipid Mediators in Asthma*

Role on Research Project: Co-Investigator

Name of Entity in which Significant Financial Interest (SFI) is held: Complexa, Inc.

Nature of the SFI: Consulting; equity interest; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Alabama, Birmingham and/or the University of Pittsburgh and licensed to Complexa, Inc.

Approximate dollar value of the SFI: Consulting income between \$20,000 - \$39,999; intellectual property rights and equity interest are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

73.

Date Disclosed: November 15, 2017

Investigator with FCOI: Ling Wang, MD, PhD

Title: Research Assistant Professor of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine

PHS Funding: NIH 5 R01 HL125886 *Antidote for Inhaled CO Poisoning Based on Mutationally Engineered Neuroglobin*

Role on Research Project: Co-Investigator

Name of the Entity in which Significant Financial Interest (SFI) is held: Globin Solutions, Inc.

Nature of the SFI: Equity interest

Approximate dollar value of the SFI: The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

74.

Date Disclosed: November 15, 2017

Investigator with FCOI: Charles F. McTiernan, PhD

Title: Research Associate Professor of Medicine, Division of Cardiology

PHS Funding: NIH 5 R01 HL125886 *Antidote for Inhaled CO Poisoning Based on Mutationally Engineered Neuroglobin*

Role on Research Project: Co-Investigator

Name of the Entity in which Significant Financial Interest (SFI) is held: Globin Solutions, Inc.

Nature of the SFI: Equity interest

Approximate dollar value of the SFI: The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

75.

Date Disclosed: November 16, 2017

Investigator with FCOI: Jesus Tejero Bravo, PhD

Title: Associate Professor of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine

PHS Funding: NIH 5 R01 HL125886 *Antidote for Inhaled CO Poisoning Based on Mutationally Engineered Neuroglobin*

Role on Research Project: Co-Investigator

Name of the Entity in which Significant Financial Interest (SFI) is held: Globin Solutions, Inc.

Nature of the SFI: Equity interest; management positions; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Globin Solutions, Inc.

Approximate dollar value of the SFI: Management position income between \$5,000 - \$9,999; intellectual property rights and equity interest are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

76.

Date Disclosed: November 16, 2017

Investigator with FCOI: Jason J. Rose, MD, MBA

Title: Assistant Professor of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine

PHS Funding: NIH 5 R01 HL125886 *Antidote for Inhaled CO Poisoning Based on Mutationally Engineered Neuroglobin*

Role on Research Project: Co-Investigator

Name of the Entity in which Significant Financial Interest (SFI) is held: Globin Solutions, Inc.

Nature of the SFI: Equity interest; management positions; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Globin Solutions, Inc.

Approximate dollar value of the SFI: Management positions income between \$10,000-\$19,999; intellectual property rights and equity interest are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

77.

Date Disclosed: November 16, 2017

Investigator with FCOI: Mark T. Gladwin, MD

Title: Chair, Department of Medicine

PHS Funding: NIH 5 R01 HL125886 *Antidote for Inhaled CO Poisoning Based on Mutationally Engineered Neuroglobin*

Role on Research Project: Principal Investigator

Name of the Entity in which Significant Financial Interest (SFI) is held: Globin Solutions, Inc.

Nature of the SFI: Equity interest; management position; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Globin Solutions, Inc.

Approximate dollar value of the SFI: Intellectual property rights and equity interest (including such interest received as compensation for management position services) are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

78.

Date Disclosed: November 20, 2017

Investigator with FCOI: Jesus Tejero Bravo, PhD

Title: Associate Professor of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine

PHS Funding: NIH 5 R21 ES027390 *Countermeasure Therapeutics for Acute Lung Injury*

Role on Research Project: Co-Investigator

Name of the Entity in which Significant Financial Interest (SFI) is held: Globin Solutions, Inc.

Nature of the SFI: Equity interest; management positions; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Globin Solutions, Inc.

Approximate dollar value of the SFI: Management position income between \$5,000 - \$9,999; intellectual property rights and equity interest are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

79.

Date Disclosed: January 26, 2018

Investigator with FCOI: John Kellum, MD

Title: Professor and Vice Chair for Research, Department of Critical Care Medicine

PHS Funding: NIH 1 R21 DK113486 *Biochemical and Reno-Protective Effects of Remote Ischemic Preconditioning on Contrast-Induced Kidney Disease*

Role on Research Project: Co-Investigator

Name of the Entity in which Significant Financial Interest (SFI) is held: bioMérieux and Astute Medical (a subsidiary of bioMérieux)

Nature of the SFI: Consulting

Approximate dollar value of the SFI: \$20,000 - \$39,999

80.

Date Disclosed: March 5, 2018

Investigator with FCOI: Stephen F. Badylak, DVM, PhD, MD

Title: Professor, Department of Surgery and Deputy Director of the McGowan Institute for Regenerative Medicine (MIRM)

PHS Funding: NIH 5 F31 CA210694 *Understanding Esophageal Adenocarcinoma Progression Using Inflammatory and Neoplastic Extracellular Matrix Hydrogels*

Role on Research Project: Primary Mentor

Name of the Entity in which Significant Financial Interest (SFI) is held: ECM Therapeutics, Inc. (formerly Restoure, Inc.)

Nature of the SFI: Equity interest; management position; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to ECM Therapeutics, Inc. (formerly Restoure, Inc.).

Approximate dollar value of the SFI: Management position income between \$100,000 - \$149,999; equity interest (including such interest received as compensation for management position services) and intellectual property rights are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

81. *FCOI eliminated April 1, 2020*

Date Disclosed: June 19, 2018

Investigator with FCOI: Dario A. Vignali, PhD

Title: Professor and Vice Chair, Department of Immunology

PHS Funding: NIH 1 R01 CA228181-01A1 *Targeting TIGIT and PD-1 in Melanoma*

Role on Research Project: Co-Investigator

Name of the Entity in which Significant Financial Interest (SFI) is held: Potenza Therapeutics, Inc.

Nature of the SFI: Equity interest

Approximate dollar value of the SFI: The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

82.

Date Disclosed: June 19, 2018

Investigator with FCOI: Dario A. Vignali, PhD

Title: Professor and Vice Chair, Department of Immunology

PHS Funding: NIH 1 R01 CA228181-01A1 *Targeting TIGIT and PD-1 in Melanoma*

Role on Research Project: Co-Investigator

Name of the Entity in which Significant Financial Interest (SFI) is held: Bristol-Myers Squibb, Inc.

Nature of the SFI: Equity interest; consulting

Approximate dollar value of the SFI: Aggregate of equity interest and consulting income between \$40,000 - \$59,999

83.

Date Disclosed: July 2, 2018

Investigator with FCOI: Jason J. Rose, MD, MBA

Title: Assistant Professor of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine

PHS Funding: NIH 1 K08 HL136857-01A1 *Discovering and Developing Recombinant Molecular Scavenging Agents for the Treatment of Carbon Monoxide Induced Cardiovascular Dysfunction*

Role on Research Project: Principal Investigator of bench, and Co-Investigator of animal research

Name of the Entity in which Significant Financial Interest (SFI) is held: Globin Solutions, Inc.

Nature of the SFI: Equity interest; management positions; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Globin Solutions, Inc.

Approximate dollar value of the SFI: Management positions income between \$10,000-\$19,999; intellectual property rights and equity interest are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

84.

Date Disclosed: August 13, 2018

Investigator with FCOI: Chakra Chennubhotla, PhD

Title: Associate Professor, Department of Computational and Systems Biology

PHS Funding: NIH 5 U01 CA204826-03 *Informatics Tools for Tumor Heterogeneity in Multiplexed Fluorescence Images*

Role on Research Project: Principal Investigator

Name of the Entity in which Significant Financial Interest (SFI) is held: SpIntellx, Inc.

Nature of the SFI: Equity interest; management position; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to SpIntellx, Inc.

Approximate dollar value of the SFI: Intellectual property rights and equity interest (including such interest received as compensation for management position services) are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

85.

Date Disclosed: August 13, 2018

Investigator with FCOI: D. Lansing Taylor, PhD

Title Distinguished Professor, Department of Computational and Systems Biology and Director, University of Pittsburgh Drug Discovery Institute

PHS Funding: NIH 5 U01 CA204826-03 *Informatics Tools for Tumor Heterogeneity in Multiplexed Fluorescence Images*

Role on Research Project: Principal Investigator

Name of the Entity in which Significant Financial Interest (SFI) is held: SpIntellx, Inc.

Nature of the SFI: Equity interest; management position; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to SpIntellx, Inc.

Approximate dollar value of the SFI: Intellectual property rights and equity interest (including such interest received as compensation for management position services) are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

86.

Date Disclosed: August 13, 2018

Investigator with FCOI: Jeffrey L. Fine, MD

Title Assistant Professor, Department of Pathology

PHS Funding: NIH 5 U01 CA204826-03 *Informatics Tools for Tumor Heterogeneity in Multiplexed Fluorescence Images*

Role on Research Project: Co-Investigator

Name of the Entity in which Significant Financial Interest (SFI) is held: SpIntellx, Inc.

Nature of the SFI: Equity interest; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to SpIntellx, Inc.

Approximate dollar value of the SFI: The interests are ones whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

87.

Date Disclosed: October 24, 2018

Investigator with FCOI: Edith Tzeng, MD

Title Professor, Department of Surgery

PHS Funding: NIH 1 R56 HL142743-01 *Engineering Biologic Topography into Vascular Grafts*

Role on Research Project: Principal Investigator

Name of the Entity in which Significant Financial Interest (SFI) is held: Aruga Technologies, LLC

Nature of the SFI: Equity interest; consulting; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and optioned to Aruga Technologies, LLC

Approximate dollar value of the SFI: The interests are ones whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

88.

Date Disclosed: October 24, 2018

Investigator with FCOI: Sachin Velankar, PhD

Title: Associate Professor, Department of Chemical and Petroleum Engineering

PHS Funding: NIH 1 R56 HL142473-01 *Engineering Biologic Topography into Vascular Grafts*

Role on Research Project: Co-Investigator

Name of the Entity in which Significant Financial Interest (SFI) is held: Aruga Technologies, LLC

Nature of the SFI: Equity interest; consulting; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and optioned to Aruga Technologies, LLC

Approximate dollar value of the SFI: The interests are ones whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

89. *FCOI eliminated January 30, 2019*

Date Disclosed: November 29, 2018

Investigator with FCOI: Steven R. Little, PhD

Title: Professor and Chair, Department of Chemical and Petroleum Engineering

PHS Funding: NIH 5 U24 DE026915-02 *Michigan-Pittsburgh-Wyss Resource Center: Supporting Regenerative Medicine in Dental, Oral and Craniofacial Technologies*

Role on Research Project: Principal Investigator

Name of the Entity in which Significant Financial Interest (SFI) is held: Lavigen, Inc.

Nature of the SFI: Equity interest; consulting; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and optioned to Lavigen, Inc.

Approximate dollar value of the SFI: Consulting income between \$20,000 - \$39,999; intellectual property rights and equity interest are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

90.

Date Disclosed: February 25, 2019

Investigator with FCOI: Dario A.A. Vignali, PhD

Title: Professor and Vice Chair, Department of Immunology

PHS Funding: NIH 1 R01 AI144422-01 *Structure, Function, and Mechanistic Analysis of LAG3*

Role on Research Project: Principal Investigator of bench and animal research, Co-Investigator of animal research

Name of the Entity in which Significant Financial Interest (SFI) is held: Bristol-Myers Squibb

Nature of the SFI: Equity interest; consulting; intellectual property rights (e.g., royalties, patents, copyrights) assigned to Johns Hopkins University/St. Jude Children's Research Hospital, Inc. and licensed to Bristol-Myers Squibb

Approximate dollar value of the SFI: Aggregate of equity interest and consulting income between \$40,000 - \$59,999; intellectual property rights between \$20,000 - \$39,999

91. *FCOI eliminated October 19, 2022*

Date Disclosed: February 25, 2019

Investigator with FCOI: Dario A.A. Vignali, PhD

Title: Professor and Vice Chair, Department of Immunology

PHS Funding: NIH 1 R01 AI144422-01 *Structure, Function, and Mechanistic Analysis of LAG3*

Role on Research Project: Principal Investigator of bench and animal research, Co-Investigator of animal research

Name of the Entity in which Significant Financial Interest (SFI) is held: Merck & Co., Inc.

Nature of the SFI: Equity interest

Approximate dollar value of the SFI: \$40,000 - \$59,999

92.

Date Disclosed: February 28, 2019

Investigator with FCOI: Creg J. Workman, PhD

Title: Research Assistant Professor, Department of Immunology

PHS Funding: NIH 1 R01 AI144422-01 *Structure, Function, and Mechanistic Analysis of LAG3*

Role on Research Project: Co-Investigator

Name of the Entity in which Significant Financial Interest (SFI) is held: Johns Hopkins University/St. Jude Children's Research Hospital, Inc.

Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to Johns Hopkins University/St. Jude Children's Research Hospital, Inc. and licensed to Bristol-Myers Squibb

Approximate dollar value of the SFI: \$20,000 - \$39,999

93.

Date Disclosed: March 11, 2019

Investigator with FCOI: William Federspiel, PhD

Title: Professor, Department of Bioengineering

PHS Funding: NIH 5 R01 HL135482-03 *Ambulatory Assist Lung for Children*

Role on Research Project: Principal Investigator of bench research and Co-Investigator of animal research

Name of the Entity in which Significant Financial Interest (SFI) is held: ALung Technologies, Inc.

Nature of the SFI: Consulting incoming; equity interest; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to ALung Technologies, Inc.

Approximate dollar value of the SFI: Consulting income between \$10,000-\$19,999; intellectual property rights and equity interest are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

94.

Date Disclosed: April 23, 2019

Investigator with FCOI: Walter Schneider, PhD

Title: Professor, Department of Psychology

PHS Funding: NIH 1 U01 EB026996-01 *Connectome 2.0: Developing the Next Generation Human MRI Scanner for Bridging Studies of the Micro-, Meso- and Macro-Connectome*

Role on Research Project: Principal Investigator

Name of the Entity in which Significant Financial Interest (SFI) is held: Psychology Software Tools, Inc.

Nature of the SFI: Equity interest

Approximate dollar value of the SFI: The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

95.

Date Disclosed: May 8, 2019

Investigator with FCOI: Walter Schneider, PhD

Title: Professor, Department of Psychology

PHS Funding: NIH 2 R44 NS103729-02 *Advancing and Calibrating Anisotropic Diffusion MR Imaging Brain Connectome with Taxon Brain Network Diffusion Phantoms*

Role on Research Project: Co-Investigator

Name of the Entity in which Significant Financial Interest (SFI) is held: Psychology Software Tools, Inc.

Nature of the SFI: Equity interest

Approximate dollar value of the SFI: The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

96.

Date Disclosed: May 17, 2019

Investigator with FCOI: John Grefenstette, PhD

Title: Professor, Department of Health Policy and Management

PHS Funding: NIH 5 P60AA006282-37 (Sub-project ID: 5610) *Framework for Behavioral Risk Models of Alcohol Problems*

Role on Research Project: Co-Investigator

Name of the Entity in which Significant Financial Interest (SFI) is held: Epistemix, Inc.

Nature of the SFI: Equity interest; management positions; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Epistemix, Inc.

Approximate dollar value of the SFI: Management positions are unpaid; equity interest and intellectual property rights are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

97.

Date Disclosed: May 17, 2019

Investigator with FCOI: Donald Burke, MD

Title: Dean Emeritus, Graduate School of Public Health and Professor, Department of Epidemiology

PHS Funding: NIH 5 U54GM088491-10 *Computational Models of Infectious Disease Threats*

Role on Research Project: Principal Investigator

Name of the Entity in which Significant Financial Interest (SFI) is held: Epistemix, Inc.

Nature of the SFI: Equity interest; management positions; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Epistemix, Inc.

Approximate dollar value of the SFI: Management positions are unpaid; equity interest and intellectual property rights are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

98.

Date Disclosed: May 17, 2019

Investigator with FCOI: John Grefenstette, PhD

Title: Professor, Department of Health Policy and Management

PHS Funding: NIH 5 U54GM088491-10 (Sub-project ID: 5080) *Models & Forecasts*

Role on Research Project: Principal Investigator

Name of the Entity in which Significant Financial Interest (SFI) is held: Epistemix, Inc.

Nature of the SFI: Equity interest; management positions; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Epistemix, Inc.

Approximate dollar value of the SFI: Management positions are unpaid; equity interest and intellectual property rights are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

99.

Date Disclosed: May 23, 2019

Investigator with FCOI: Donald Burke, MD

Title: Dean Emeritus, Graduate School of Public Health and Professor, Department of Epidemiology

PHS Funding: CDC 75D30118C01377 *Advancing Analytics to Improve Actionable Changes in the Opioid Overdose Epidemic*

Role on Research Project: Principal Investigator

Name of the Entity in which Significant Financial Interest (SFI) is held: Epistemix, Inc.

Nature of the SFI: Equity interest; management positions; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Epistemix, Inc.

Approximate dollar value of the SFI: Management positions are unpaid; equity interest and intellectual property rights are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

100.

Date Disclosed: May 23, 2019

Investigator with FCOI: John Grefenstette, PhD

Title: Professor, Department of Health Policy and Management

PHS Funding: CDC 75D30118C01377 *Advancing Analytics to Improve Actionable Changes in the Opioid Overdose Epidemic*

Role on Research Project: Co-Investigator

Name of the Entity in which Significant Financial Interest (SFI) is held: Epistemix, Inc.

Nature of the SFI: Equity interest; management positions; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Epistemix, Inc.

Approximate dollar value of the SFI: Management positions are unpaid; equity interest and intellectual property rights are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

101.

Date Disclosed: June 11, 2019

Investigator with FCOI: Shelby O'Connor, PhD

Title: Associate Professor of Pathology and Laboratory Medicine at the University of Wisconsin – Madison

PHS Funding: NIH 1R01AI142662 *Effects of HIV SIV on unconventional T cells in immunity to M. tuberculosis in pre adolescents*

Role on Research Project: Principal Investigator

Name of Entity in which Significant Financial Interest (SFI) is held: Battelle Memorial Institute

Nature of the SFI: Consulting

Approximate dollar value of the SFI: \$5,000 - \$9,999

102. *FCOI eliminated April 27, 2021*

Date Disclosed: June 25, 2019

Investigator with FCOI: Joseph Glorioso, PhD

Title: Professor, Department of Microbiology & Molecular Genetics

PHS Funding: NIH 5 R01 CA222804-02 *Arming Oncolytic HSV Vectors to Induce Anti-GBM Immune Responses in Syngeneic Mice*

Role on Research Project: Co-Investigator

Name of the Entity in which Significant Financial Interest (SFI) is held: Oncorus, Inc.

Nature of the SFI: Consulting; equity interest; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Oncorus

Approximate dollar value of the SFI: Consulting income between \$100,000 - \$149,999; equity interest between \$450,000 - \$499,999; intellectual property rights is an interest whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

103. *FCOI eliminated April 27, 2021*

Date Disclosed: June 25, 2019

Investigator with FCOI: William Goins, PhD

Title: Research Assistant Professor, Department of Microbiology & Molecular Genetics

PHS Funding: NIH 5 R01 CA222804-02 *Arming Oncolytic HSV Vectors to Induce Anti-GBM Immune Responses in Syngeneic Mice*

Role on Research Project: Co-Investigator

Name of the Entity in which Significant Financial Interest (SFI) is held: Oncorus, Inc.

Nature of the SFI: Consulting; equity interest

Approximate dollar value of the SFI: Consulting income between \$5,000-\$9,999; equity interest between \$5,000 - \$9,999.

104.

Date Disclosed: June 24, 2019

Investigator with FCOI: Carlos Malvestutto, M.D., M.P.H.

Title: Assistant Professor, Ohio State University

PHS Funding: NIH 5 UM 1AI068619 *LOC: HIV Prevention Trials Network*

Role on Research Project: Co-Investigator

Name of Entity in which Significant Financial Interest (SFI) is held: ViiV Healthcare

Nature of SFI: Consulting

Approximate dollar value: \$10,000 - \$19,999

105.

Date Disclosed: July 10, 2019

Investigator with FCOI: Jennifer Grandis, M.D.

Title: Professor and Associate Vice Chancellor for Clinical and Translational Research, University of California, San Francisco

PHS Funding: NIH 5 P50 CA097190-15 *Head and Neck Cancer Spore*

Role on Research Project: Principal Investigator

Name of Entity in which Significant Financial Interest (SFI) is held: STAT3 Therapeutics

Nature of SFI: Equity interest

Approximate dollar value: \$5,000 - \$9,999

106.

Date Disclosed: August 8, 2019

Investigator with FCOI: Mark T. Gladwin, MD

Title: Chair, Department of Medicine

PHS Funding: NIH 5 P01 HL103455-09 *Therapeutic Targeting of Vascular Subphenotypes of Lung Disease*

Role on Research Project: Co-Investigator

Name of the Entity in which Significant Financial Interest (SFI) is held: Globin Solutions, Inc.

Nature of the SFI: Equity interest; management position; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the NIH and licensed to Globin Solutions, Inc.

Approximate dollar value of the SFI: Intellectual property rights and equity interest (including such interest received as compensation for management position services) are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

107.

Date Disclosed: August 8, 2019

Investigator with FCOI: Charles F. McTiernan, PhD

Title: Research Associate Professor of Medicine, Division of Cardiology

PHS Funding: NIH 5 P01 HL103455-09 *Therapeutic Targeting of Vascular Subphenotypes of Lung Disease*

Role on Research Project: Co-Investigator

Name of the Entity in which Significant Financial Interest (SFI) is held: Globin Solutions, Inc.

Nature of the SFI: Equity interest

Approximate dollar value of the SFI: The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

108.

Date Disclosed: October 10, 2019

Investigator with FCOI: Bruce Freeman, PhD

Title: Professor and Chair, Department of Pharmacology and Chemical Biology

PHS Funding: NIH 1 R56 CA233817-01A1 *Inhibition of DNA double strand break repair in TNBC by nitro-fatty acids*

Role on Research Project: Co-Investigator

Name of the Entity in which Significant Financial Interest (SFI) is held: Creegh Pharmaceuticals, Inc.

Nature of the SFI: Equity interest; management positions; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and optioned to Creegh Pharmaceuticals, Inc.

Approximate dollar value of the SFI: Equity interest and intellectual property rights are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value. Management positions are unpaid.

109.

Date Disclosed: November 21, 2019

Investigator with FCOI: Shantanu Chakrabartty, PhD

Title: Clifford Murphy Professor of Electrical & Systems Engineering at Washington University in St. Louis

PHS Funding: NIH 1R21AR075242-01 *Wireless, Self-Powered Sensors for Continuous and Longer-Term Monitoring of Spinal Fusion Process*

Role on Research Project: Principal Investigator

Name of Entity in which Significant Financial Interest (SFI) is held: Piezonix, LLC

Nature of the SFI: Equity interest

Approximate dollar value of the SFI: The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

110.

Date Disclosed: December 3, 2019

Investigator with FCOI: Mark T. Gladwin, MD

Title: Chair, Department of Medicine

PHS Funding: NIH 1 R01 AG058883-01A1 *Nitrite Therapy to Improve Mitochondrial Energetics and Physical Activity in Older Adults*

Role on Research Project: Co-Investigator

Name of the Entity in which Significant Financial Interest (SFI) is held: Globin Solutions, Inc.

Nature of the SFI: Equity interest; management position; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the NIH and licensed to Globin Solutions, Inc.

Approximate dollar value of the SFI: Intellectual property rights and equity interest (including such interest received as compensation for management position services) are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

111.

Date Disclosed: December 31, 2019

Investigator with FCOI: Charles S. Sfeir, DDS, PhD

Title: Chair, Department of Periodontics and Preventative Dentistry

PHS Funding: NIH 5 U24 DE026915-03 *Michigan-Pittsburgh-Wyss Resource Center: Supporting Regenerative Medicine in Dental, Oral and Craniofacial Technologies*

Role on Research Project: Co-Investigator

Name of the Entity in which Significant Financial Interest (SFI) is held: Emergence Dental, Inc.

Nature of the SFI: Equity interest; management positions; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and optioned to Emergence Dental, Inc.

Approximate dollar value of the SFI: Equity interest and intellectual property rights are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value. Management positions are unpaid.

112.

Date Disclosed: February 6, 2020

Investigator with FCOI: Kelly L. Williams, DMD

Title: Assistant Professor, Department of Periodontics and Preventative Dentistry

PHS Funding: NIH 5 U24 DE026915-03 *Michigan-Pittsburgh-Wyss Resource Center: Supporting Regenerative Medicine in Dental, Oral and Craniofacial Technologies*

Role on Research Project: Co-Investigator

Name of the Entity in which Significant Financial Interest (SFI) is held: Emergence Dental, Inc.

Nature of the SFI: Consulting; equity interest

Approximate dollar value of the SFI: The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

113.

Date Disclosed: February 26, 2020

Investigator with FCOI: Tamar Krishnamurti, PhD

Title: Assistant Professor, Division of General Internal Medicine, Department of Medicine

PHS Funding: NIH 1 R21 MH119450-01A1 *Identification and Prediction of Peripartum Depression from Natural Language Collected in a Mobile Health App*

Role on Research Project: Principal Investigator

Name of the Entity in which Significant Financial Interest (SFI) is held: Naima Health, LLC

Nature of the SFI: Equity interest; management positions; consulting; intellectual property rights (e.g., royalties, patents, copyrights) assigned to Carnegie Mellon University and licensed to Naima Health, LLC

Approximate dollar value of the SFI: Income from management positions and consulting between \$20,000 - \$39,999; Equity interest and intellectual property rights are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

114.

Date Disclosed: February 26, 2020

Investigator with FCOI: Hyagriv Simhan, MD, MS

Title: Professor, Department of Obstetrics, Gynecology, and Reproductive Sciences

PHS Funding: NIH 1 R21 MH119450-01A1 *Identification and Prediction of Peripartum Depression from Natural Language Collected in a Mobile Health App*

Role on Research Project: Co-Investigator

Name of the Entity in which Significant Financial Interest (SFI) is held: Naima Health, LLC

Nature of the SFI: Equity interest; management position; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Naima Health, LLC

Approximate dollar value of the SFI: Management position is unpaid; Equity interest and intellectual property rights are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

115.

Date Disclosed: April 14, 2020

Investigator with FCOI: Lee M. Ritterband, Ph.D.

Title: Professor, Psychiatry and Neurobehavioral Sciences, University of Virginia

PHS Funding: NIH 5 R01 HL131587-03 *Improving Asthma Control Using Internet-Based Cognitive-Behavioral Treatment for Insomnia*

Role on Research Project: Principal Investigator

Name of the Entity in which Significant Financial Interest (SFI) is held: BeHealth Solutions, LLC

Nature of the SFI: Equity interest

Approximate dollar value of the SFI: \$20,000-39,999

116.

Date Disclosed: April 29, 2020

Investigator with FCOI: Lori Birder, PhD

Title: Professor, Division of Renal-Electrolyte, Department of Medicine

PHS Funding: NIH 1 R56 AG063753-01 *Role of Purine Dysregulation in the Underactive Bladder*

Role on Research Project: Principal Investigator

Name of the Entity in which Significant Financial Interest (SFI) is held: Deleon Biosciences, Inc.

Nature of the SFI: Equity interest; management position; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and optioned to Deleon Biosciences, Inc.

Approximate dollar value of the SFI: Intellectual property rights and equity interest (including such interest received as compensation for management position services) are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

117.

Date Disclosed: April 29, 2020

Investigator with FCOI: Edwin K. Jackson, PhD

Title: Professor, Department of Pharmacology and Chemical Biology

PHS Funding: NIH 1 R56 AG063753-01 *Role of Purine Dysregulation in the Underactive Bladder*

Role on Research Project: Principal Investigator

Name of the Entity in which Significant Financial Interest (SFI) is held: Deleon Biosciences, Inc.

Nature of the SFI: Equity interest; management position; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and optioned to Deleon Biosciences, Inc.

Approximate dollar value of the SFI: Intellectual property rights and equity interest (including such interest received as compensation for management position services) are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

118.

Date Disclosed: June 8, 2020

Investigator with FCOI: Jesus Tejero Bravo, PhD

Title: Associate Professor of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine

PHS Funding: NIH 1 R42 ES031993-01 *Hemoglobin-Based Antidotes for the Treatment of Carbon Monoxide Poisoning*

Role on Research Project: Principal Investigator

Name of the Entity in which Significant Financial Interest (SFI) is held: Globin Solutions, Inc.

Nature of the SFI: Equity interest; management positions; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Globin Solutions, Inc.

Approximate dollar value of the SFI: Management position income between \$5,000 - \$9,999; intellectual property rights and equity interest are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

119.

Date Disclosed: June 24, 2020

Investigator with FCOI: Mark T. Gladwin, MD

Title: Chair, Department of Medicine

PHS Funding: NIH 1 R42 ES031993-01 *Hemoglobin-Based Antidotes for the Treatment of Carbon Monoxide Poisoning*

Role on Research Project: Co-Investigator

Name of the Entity in which Significant Financial Interest (SFI) is held: Globin Solutions, Inc.

Nature of the SFI: Equity interest; management position; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Globin Solutions, Inc.

Approximate dollar value of the SFI: Intellectual property rights and equity interest (including such interest received as compensation for management position services) are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

120.

Date Disclosed: July 28, 2020

Investigator with FCOI: Kacey G. Marra, PhD

Title: Professor, Department of Plastic Surgery

PHS Funding: NIH 1 U24 DE029462-01 *Michigan-Pittsburgh-Wyss Regenerative Medicine Resource Center: Advancing Dental, Oral, and Craniofacial Regeneration to Clinical Trial Initiation*

Role on Research Project: Principal Investigator

Name of the Entity in which Significant Financial Interest (SFI) is held: AxoMax Technologies, Inc.

Nature of the SFI: Equity interest; management position; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Globin Solutions, Inc.

Approximate dollar value of the SFI: Management position is unpaid; Intellectual property rights and equity interest are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

121.

Date Disclosed: August 24, 2020

Investigator with FCOI: Samira Kiani, MD

Title: Associate Professor, Department of Pathology

PHS Funding: NIH 7 R01 EB024562-03 *CRISPR logic circuits for safer and controllable gene therapies*

Role on Research Project: Principal Investigator

Name of the Entity in which Significant Financial Interest (SFI) is held: SafeGen Therapeutics

Nature of the SFI: Equity interest; management position; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the Arizona State University and optioned and/or licensed to SafeGen Therapeutics

Approximate dollar value of the SFI: Management position is unpaid; Intellectual property rights and equity interest are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

122.

Date Disclosed: August 24, 2020

Investigator with FCOI: Mo Reza Ebrahimkhani, MD

Title: Associate Professor, Department of Pathology

PHS Funding: NIH 7 R01 EB024562-03 *CRISPR logic circuits for safer and controllable gene therapies*

Role on Research Project: Co-Investigator

Name of the Entity in which Significant Financial Interest (SFI) is held: SafeGen Therapeutics

Nature of the SFI: Equity interest (held directly by spouse); management position (held directly by spouse); intellectual property rights (e.g., royalties, patents, copyrights) assigned to the Arizona State University and optioned and/or licensed to SafeGen Therapeutics

Approximate dollar value of the SFI: Management position is unpaid; Intellectual property rights and equity interest are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

123.

Date Disclosed: August 30, 2020

Investigator with FCOI: Donald Burke, MD

Title: Dean Emeritus, Graduate School of Public Health and Professor, Department of Epidemiology

PHS Funding: CDC 1 U01 IP001141-01 *Individual-based Simulation of Seasonal and Pandemic Influenza Epidemics*

Role on Research Project: Co-investigator

Name of the Entity in which Significant Financial Interest (SFI) is held: Epistemix, Inc.

Nature of the SFI: Equity interest; management positions; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Epistemix, Inc.

Approximate dollar value of the SFI: Management positions are unpaid; equity interest and intellectual property rights are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

124.

Date Disclosed: October 30, 2020

Investigator with FCOI: Jason J. Rose, MD, MBA

Title: Assistant Professor of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine

PHS Funding: NIH 5 R01 HL133003-04 *Heme-induced platelet mtROS drives TSP1 release to accelerate PH pathogenesis*

Role on Research Project: Co-investigator

Name of the Entity in which Significant Financial Interest (SFI) is held: Globin Solutions, Inc.

Nature of the SFI: Equity interest; management positions; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Globin Solutions, Inc.

Approximate dollar value of the SFI: Management positions income between \$10,000-\$19,999; intellectual property rights and equity interest are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

125.

Date Disclosed: November 2, 2020

Investigator with FCOI: George K. Gittes, MD

Title: Chief, Division of Pediatric Surgery, Department of Surgery

PHS Funding: NIH 5 R01 DK112836-04 *Endogenous alpha-to-beta cell transdifferentiation in diabetes*

Role on Research Project: Principal Investigator

Name of the Entity in which Significant Financial Interest (SFI) is held: Genprex, Inc.

Nature of the SFI: Consulting; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Genprex, Inc.

Approximate dollar value of the SFI: Consulting income between \$20,000-\$39,999; intellectual property rights is an interest whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

126.

Date Disclosed: November 2, 2020

Investigator with FCOI: George K. Gittes, MD

Title: Chief, Division of Pediatric Surgery, Department of Surgery

PHS Funding: NIH 2 R01 DK120377-03 *Alpha cell conversion to beta cells in non-human primates*

Role on Research Project: Principal Investigator

Name of the Entity in which Significant Financial Interest (SFI) is held: Genprex, Inc.

Nature of the SFI: Consulting; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Genprex, Inc.

Approximate dollar value of the SFI: Consulting income between \$20,000-\$39,999; intellectual property rights is an interest whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

127.

Date Disclosed: November 20, 2020

Investigator with FCOI: Jesus Tejero Bravo, PhD

Title: Associate Professor of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine

PHS Funding: NIH 5 P01 HL103455-10 *Therapeutic Targeting of Vascular Subphenotypes of Lung Disease*

Role on Research Project: Co-investigator

Name of the Entity in which Significant Financial Interest (SFI) is held: Globin Solutions, Inc.

Nature of the SFI: Equity interest; management positions; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Globin Solutions, Inc.

Approximate dollar value of the SFI: Management position income between \$5,000 - \$9,999; intellectual property rights and equity interest are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

128.

Date Disclosed: December 2, 2020

Investigator with FCOI: Jason Wilson, MD

Title: Associate Professor, College of Medicine Internal Medicine, University of South Florida

PHS Funding: NIH 1 OT2 HL156812-01 *ACTIV Integration of Host-targeting Therapies for COVID-19 Administrative Coordinating Center*

Role on Research Project: Principal Investigator

Name of the Entity in which Significant Financial Interest (SFI) is held: Pfizer, Inc.

Nature of the SFI: Consulting

Approximate dollar value of the SFI: \$10,000 - \$19,999

129.

Date Disclosed: January 25, 2021

Investigator with FCOI: Jingjing Sun, PhD

Title: Research Instructor, Department of Pharmaceutical Sciences

PHS Funding: NIH 1 R21 CA249649-01A1 *Tumor-permeable nanoparticles for enhanced pancreatic cancer immunochemotherapy*

Role on Research Project: Principal Investigator

Name of the Entity in which Significant Financial Interest (SFI) is held: Duo Oncology, Inc.

Nature of the SFI: Equity interest; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and optioned to Duo Oncology, Inc.

Approximate dollar value of the SFI: Equity interest and intellectual property rights are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

130.

Date Disclosed: January 25, 2021

Investigator with FCOI: Song Li, MD, PhD

Title: Professor, Department of Pharmaceutical Sciences

PHS Funding: NIH 1 R21 CA249649-01A1 *Tumor-permeable nanoparticles for enhanced pancreatic cancer immunochemotherapy*

Role on Research Project: Co-investigator

Name of the Entity in which Significant Financial Interest (SFI) is held: Duo Oncology, Inc.

Nature of the SFI: Management position; equity interest; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and optioned to Duo Oncology, Inc.

Approximate dollar value of the SFI: Equity interest (including such interest received as compensation for management position services) and intellectual property rights are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

131.

Date Disclosed: February 17, 2021

Investigator with FCOI: Jan Drappatz, MD

Title: Associate Professor, Department of Neurology

PHS Funding: NIH 5 UM1 CA137443-10 *Adult Brain Tumor Consortium (ABTC)*

Role on Research Project: Co-investigator

Name of the Entity in which Significant Financial Interest (SFI) is held: Bristol-Myers Squibb

Nature of the SFI: Equity interest

Approximate dollar value of the SFI: \$20,000 - \$39,999

132.

Date Disclosed: March 12, 2021

Investigator with FCOI: Bruce Freeman, PhD

Title: Professor and Chair, Department of Pharmacology and Chemical Biology

PHS Funding: NIH 1 R21 HL152312-01A1 *Focal delivery of nitro-oleic acid using ultrasound targeted microbubble cavitation for the treatment of microvascular obstruction*

Role on Research Project: Co-investigator

Name of the Entity in which Significant Financial Interest (SFI) is held: Creegh Pharmaceuticals, Inc.

Nature of the SFI: Management position; equity interest; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and optioned to Creegh Pharmaceuticals, Inc.

Approximate dollar value of the SFI: Equity interest (including such interest received as compensation for management position services) and intellectual property rights are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

133.

Date Disclosed: March 25, 2021

Investigator with FCOI: Robert M.Q. Shanks, PhD

Title: Associate Professor, Department of Ophthalmology

PHS Funding: NIH 3 R01 EY027331-04S1 *NOT-NS-20-030: Use of anchored biologics to treat vesicant induced neovascularization*

Role on Research Project: Principal Investigator

Name of the Entity in which Significant Financial Interest (SFI) is held: AnkyrBio LLC

Nature of the SFI: Equity interest; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and optioned to AnkyrBio LLC

Approximate dollar value of the SFI: Equity interest and intellectual property rights are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

134.

Date Disclosed: March 25, 2021

Investigator with FCOI: Jes K. Klarlund, PhD

Title: Adjunct Associate Professor, Department of Ophthalmology

PHS Funding: NIH 3 R01 EY027331-04S1 *NOT-NS-20-030: Use of anchored biologics to treat vesicant induced neovascularization*

Role on Research Project: Co-investigator

Name of the Entity in which Significant Financial Interest (SFI) is held: AnkyrBio LLC

Nature of the SFI: Management position; equity interest; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and optioned to AnkyrBio LLC

Approximate dollar value of the SFI: Management position income between \$60,000 - \$79,999; equity interest and intellectual property rights are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

135.

Date Disclosed: April 1, 2021

Investigator with FCOI: Sanjay Mathew, MD

Title: Professor, Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine

PHS Funding: NIH 5 R01 MH113857-04 *Testing a Synergistic, Neuroplasticity-Based Intervention for Depressive Neurocognition*

Role on Research Project: Principal Investigator

Name of the Entity in which Significant Financial Interest (SFI) is held: Alkermes

Nature of the SFI: Consulting

Approximate dollar value of the SFI: \$60,000 - \$79,999

136.

Date Disclosed: April 1, 2021

Investigator with FCOI: Sanjay Mathew, MD

Title: Professor, Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine

PHS Funding: NIH 5 R01 MH113857-04 *Testing a Synergistic, Neuroplasticity-Based Intervention for Depressive Neurocognition*

Role on Research Project: Principal Investigator

Name of the Entity in which Significant Financial Interest (SFI) is held: Allergan

Nature of the SFI: Consulting

Approximate dollar value of the SFI: \$5,000 - \$9,999

137.

Date Disclosed: April 1, 2021

Investigator with FCOI: Sanjay Mathew, MD

Title: Professor, Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine

PHS Funding: NIH 5 R01 MH113857-04 *Testing a Synergistic, Neuroplasticity-Based Intervention for Depressive Neurocognition*

Role on Research Project: Principal Investigator

Name of the Entity in which Significant Financial Interest (SFI) is held: Intra-Cellular Therapies, Inc.

Nature of the SFI: Consulting

Approximate dollar value of the SFI: \$5,000 - \$9,999

138.

Date Disclosed: April 1, 2021

Investigator with FCOI: Sanjay Mathew, MD

Title: Professor, Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine

PHS Funding: NIH 5 R01 MH113857-04 *Testing a Synergistic, Neuroplasticity-Based Intervention for Depressive Neurocognition*

Role on Research Project: Principal Investigator

Name of the Entity in which Significant Financial Interest (SFI) is held: Janssen Research and Development

Nature of the SFI: Consulting

Approximate dollar value of the SFI: \$20,000 - \$39,999

139.

Date Disclosed: April 15, 2021

Investigator with FCOI: Stephen Y. Chan, MD, PhD

Title: Professor, Division of Cardiology, Department of Medicine

PHS Funding: NIH 5 R01 HL138437-04 *Molecular Drivers of Vascular Stiffness and Metabolic Dysfunction in HIV-Induced Pulmonary Arterial Hypertension*

Role on Research Project: Principal Investigator

Name of the Entity in which Significant Financial Interest (SFI) is held: Synhale Therapeutics, Inc.

Nature of the SFI: Management positions; equity interest; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and University of Pittsburgh/Brigham Woman's Hospital and optioned to Synhale Therapeutics, Inc.

Approximate dollar value of the SFI: Management positions are unpaid; equity interest and intellectual property rights are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

140.

Date Disclosed: May 20, 2021

Investigator with FCOI: Stephen F. Badylak, DMV, PhD, MD

Title: Professor, Department of Surgery and Deputy Director of the McGowan Institute for Regenerative Medicine (MIRM)

PHS Funding: NIH 1 R21 NS118399-01A1 *Enhancing Neurogenesis for Brain Tissue Regeneration*

Role on Research Project: Co-investigator

Name of the Entity in which Significant Financial Interest (SFI) is held: ECM Therapeutics, Inc.

Nature of the SFI: Management position; equity interest; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to ECM Therapeutics, Inc.

Approximate dollar value of the SFI: Management position income between \$100,000 - \$149,999; equity interest (including such interest received as compensation for management position services) and intellectual property rights are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

141.

Date Disclosed: May 24, 2021

Investigator with FCOI: Robert Desnick, PhD, MD, DSc

Title: Professor & Chair Emeritus, Genetics and Genomic Sciences, Mount Sinai School of Medicine

PHS Funding: NIH 1 R01 DK124412-01A1 *Beta-catenin inhibition as a novel therapeutic strategy for porphyria*

Role on Research Project: Co-investigator

Name of the Entity in which Significant Financial Interest (SFI) is held: Alnylam Pharmaceuticals

Nature of the SFI: Consulting

Approximate dollar value of the SFI: \$20,000 - \$39,999

142.

Date Disclosed: July 21, 2021

Investigator with FCOI: Lillian Chong

Title: Associate Professor, Department of Chemistry

PHS Funding: NIH 5 R01 GM115805-07 *High-performance weighted ensemble software for simulation of complex bio-events*

Role on Research Project: Principal Investigator

Name of the Entity in which Significant Financial Interest (SFI) is held: OpenEye Scientific

Nature of the SFI: Consulting

Approximate dollar value of the SFI: \$20,000 - \$39,999

143.

Date Disclosed: August 11, 2021

Investigator with FCOI: Mark E. Schurdak, PhD

Title: Visiting Research Associate Professor, Department of Computational & Systems Biology

PHS Funding: NIH 2 U24 TR002632-03 *Development and Commercialization of the Microphysiological Systems Database as a Sustainable Resource*

Role on Research Project: Principal Investigator

Name of the Entity in which Significant Financial Interest (SFI) is held: BioSystics, Inc.

Nature of the SFI: Management position; equity interest; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to BioSystics, Inc.

Approximate dollar value of the SFI: Equity interest (including such interest received as compensation for management position services) and intellectual property rights are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

144.

Date Disclosed: August 11, 2021

Investigator with FCOI: Albert Gough, PhD

Title: Research Associate Professor, Department of Computational & Systems Biology

PHS Funding: NIH 2 U24 TR002632-03 *Development and Commercialization of the Microphysiological Systems Database as a Sustainable Resource*

Role on Research Project: Principal Investigator

Name of the Entity in which Significant Financial Interest (SFI) is held: BioSystics, Inc.

Nature of the SFI: Management position; equity interest; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to BioSystics, Inc.

Approximate dollar value of the SFI: Equity interest (including such interest received as compensation for management position services) and intellectual property rights are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

145.

Date Disclosed: August 11, 2021

Investigator with FCOI: D. Lansing Taylor, PhD

Title: Professor, Department of Computational & Systems Biology

PHS Funding: NIH 2 U24 TR002632-03 *Development and Commercialization of the Microphysiological Systems Database as a Sustainable Resource*

Role on Research Project: Principal Investigator

Name of the Entity in which Significant Financial Interest (SFI) is held: BioSystics, Inc.

Nature of the SFI: Management position; equity interest; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to BioSystics, Inc.

Approximate dollar value of the SFI: Equity interest (including such interest received as compensation for management position services) and intellectual property rights are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

146.

Date Disclosed: August 24, 2021

Investigator with FCOI: Leah Byrne, PhD

Title: Assistant Professor, Department of Ophthalmology

PHS Funding: NIH 5 UG3 MH120094-03 *A Massive Library of AAVs to Target Transcriptionally-Defined Primate Cell Types*

Role on Research Project: Co-investigator

Name of the Entity in which Significant Financial Interest (SFI) is held: Newsight Therapeutics

Nature of the SFI: Management position; equity interest

Approximate dollar value of the SFI: Equity interest (including such interest received as compensation for management position services) are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

147.

Date Disclosed: November 16, 2021

Investigator with FCOI: Samira Kiani, MD

Title: Associate Professor, Department of Pathology

PHS Funding: NIH 5 R01 EB024562-04 *CRISPR logic circuits for safer and controllable gene therapies*

Role on Research Project: Principal Investigator

Name of the Entity in which Significant Financial Interest (SFI) is held: GenexGen Inc.

Nature of the SFI: Equity interest; management position

Approximate dollar value of the SFI: Management position is unpaid; equity interest are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

148.

Date Disclosed: December 15, 2021

Investigator with FCOI: Charles S. Sfeir, DDS, PhD

Title: Chair, Department of Periodontics and Preventative Dentistry

PHS Funding: NIH 2 R44DE024919-05 *Commercialization Readiness Program (CRP) for Bioabsorbable Magnesium (Mg) Implants for Craniomaxillofacial Surgical Systems*

Role on Research Project: Principal Investigator

Name of the Entity in which Significant Financial Interest (SFI) is held: Emergence Dental, Inc.

Nature of the SFI: Equity interest; management positions; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and optioned to Emergence Dental, Inc.

Approximate dollar value of the SFI: Equity interest and intellectual property rights are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value. Management positions are unpaid.

149.

Date Disclosed: February 7, 2022

Investigator with FCOI: Dario A.A. Vignali, PhD

Title: Professor and Vice Chair, Department of Immunology

PHS Funding: NIH 1 P50 CA254865-01A1 *Melanoma and Skin Cancer SPORE*

Role on Research Project: Principal Investigator of bench research

Name of the Entity in which Significant Financial Interest (SFI) is held: Bristol-Myers Squibb

Nature of the SFI: Equity interest; consulting; intellectual property rights (e.g., royalties, patents, copyrights) assigned to Johns Hopkins University/St. Jude Children's Research Hospital, Inc. and licensed to Bristol-Myers Squibb

Approximate dollar value of the SFI: Aggregate of equity interest and consulting income between \$20,000 - \$29,999; intellectual property rights between \$80,000 - \$99,999

150.

Date Disclosed: February 8, 2022

Investigator with FCOI: Nick Allen, PhD

Title: Professor; Department of Psychology; University of Oregon

PHS Funding: NIH 1 R01 MH125971-01 *Early Intervention for Youth At-Risk for Bipolar Disorder*

Role on Research Project: Co-investigator

Name of the Entity in which Significant Financial Interest (SFI) is held: Ksana Health

Nature of the SFI: Equity interest; management position

Approximate dollar value of the SFI: Equity interest are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value. Management positions are \$20,000 - \$39,999.

151.

Date Disclosed: February 8, 2022

Investigator with FCOI: Robert Gaunt

Title: Associate Professor, Department of Physical Medicine and Rehabilitation

PHS Funding: NIH 5 UH3 NS107714-03 *A Biomimetic Approach Towards a Dexterous Neuroprosthesis*

Role on Research Project: Co-investigator

Name of the Entity in which Significant Financial Interest (SFI) is held: Blackrock Microsystems, LLC

Nature of the SFI: Consulting

Approximate dollar value of the SFI: \$100,000 - \$149,999

152.

Date Disclosed: March 21, 2022

Investigator with FCOI: Louis D. Fallo, Jr., M.D., Ph.D.

Title: Professor and Chair of Dermatology

PHS Funding: NIH 1 P50 CA254865-01A1 (Sub-project ID: 5877) *SPORE in Skin Cancer*

Role on Research Project: Principal Investigator of bench and Co-Investigator of human subject, research

Name of Entity in which Significant Financial Interest (SFI) is held: SkinJect

Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to SkinJect; equity interest

Approximate dollar value of the SFI: IP - \$5,000 - \$9,999; Equity - The interests are ones whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

153.

Date Disclosed: April 22, 2022

Investigator with FCOI: Charles Jonassaint, PhD MHS.

Title: Assistant Professor of Medicine, Social Work and Clinical and Translational Science

PHS Funding: NIH 5 UH3 HL143192-03 *1/2 Sickle Cell Disease and Cardiovascular Risk - Red cell Exchange Trial (SCD-CARRE Trial)*

Role on Research Project: Co-Investigator of human subject, research

Name of Entity in which Significant Financial Interest (SFI) is held: Expressive Painimation

Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Expressive Painimation; equity interest; management position

Approximate dollar value of the SFI: Equity/IP/management position - The interests are ones whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

154.

Date Disclosed: April 25, 2022

Investigator with FCOI: Charles Jonassaint, PhD MHS.

Title: Assistant Professor of Medicine, Social Work and Clinical and Translational Science

PHS Funding: NIH 1 RM1 DA055311-01 *Tailored Retention and Engagement for Equitable Treatment of OUD and Pain (TREETOP)*

Role on Research Project: Co-Investigator of human subject, research

Name of Entity in which Significant Financial Interest (SFI) is held: Expressive Painimation

Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Expressive Painimation; equity interest; management position

Approximate dollar value of the SFI: Equity/IP/management position - The interests are ones whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

155.

Date Disclosed: May 9, 2022

Investigator with FCOI: Joseph C. Glorioso III, PhD

Title: Professor of Microbiology and Molecular Genetics

PHS Funding: NIH 1 UG3 NS123964-01 *Disease Modifying Analgesia with CA8 Gene Therapy*

Role on Research Project: Principal investigator of bench research

Name of Entity in which Significant Financial Interest (SFI) is held: Adolore Therapeutics, Inc.

Nature of the SFI: Equity interest; management position

Approximate dollar value of the SFI: Equity/management position - The interests are ones whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

156.

Date Disclosed: May 9, 2022

Investigator with FCOI: Joseph C. Glorioso III, PhD

Title: Professor of Microbiology and Molecular Genetics

PHS Funding: NIH 1 UG3 NS123964-01 *Disease Modifying Analgesia with CA8 Gene Therapy*

Role on Research Project: Principal investigator of bench research

Name of the Entity in which Significant Financial Interest (SFI) is held: RePlay Holdings LLC

Nature of the SFI: Equity interest; consulting

Approximate dollar value of the SFI: Equity - The interests are ones whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value; consulting - \$100,000 - \$149,999

157.

Date Disclosed: May 11, 2022

Investigator with FCOI: Yi Shi, PhD

Title: Associate Professor, Director for Center of Protein Engineering and Therapeutics;
Icahn School of Medicine at Mount Sinai

PHS Funding: NIH 1 R21 CA261737-01 *Using nanobodies to increase the sensitivity and resolution of chromatin profiling through uliCUT&RUN*

Role on Research Project: Principal investigator of bench research

Name of the Entity in which Significant Financial Interest (SFI) is held: Antenna Biotechnology, Inc.

Nature of the SFI: Equity interest

Approximate dollar value of the SFI: Equity interest are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

158.

Date Disclosed: July 27, 2022

Investigator with FCOI: Mo Reza Ebrahimkhani, MD

Title: Associate Professor, Department of Pathology

PHS Funding: NIH 5 R01 EB 024562-04 *CRISPR logic circuits for safer and controllable gene therapies*

Role on Research Project: Co-Investigator

Name of the Entity in which Significant Financial Interest (SFI) is held: GenexGen

Nature of the SFI: Equity interest; management position

Approximate dollar value of the SFI: Management position is unpaid; Equity interest are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

159.

Date Disclosed: August 3, 2022

Investigator with FCOI: Marco Fazzari, PhD

Title: Assistant Professor, Department of Pharmacology and Chemical Biology

PHS Funding: NIH 5 R21 HL152312-02 *Focal delivery of nitro-oleic acid using ultrasound targeted microbubble cavitation for the treatment of microvascular obstruction*

Role on Research Project: Co-investigator

Name of the Entity in which Significant Financial Interest (SFI) is held: Creegh Pharmaceuticals, Inc.

Nature of the SFI: Equity interest

Approximate dollar value of the SFI: Equity interest values are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

160.

Date Disclosed: August 24, 2022

Investigator with FCOI: Bruce Freeman, PhD

Title: Professor and Chair, Department of Pharmacology and Chemical Biology

PHS Funding: NIH 1 R61 HL157069-01A1 *LIMA: Lipid anti-Inflammatory Mediators in Asthma to reduce airway hyperresponsiveness in obese asthmatics*

Role on Research Project: Co-investigator

Name of the Entity in which Significant Financial Interest (SFI) is held: Creegh Pharmaceuticals, Inc.

Nature of the SFI: Management position; equity interest

Approximate dollar value of the SFI: Equity interest (including such interest received as compensation for management position services) are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

161.

Date Disclosed: September 23, 2022

Investigator with FCOI: Jordi Ochando, PhD

Title: Associate Professor, Oncological Sciences, Nephrology and Pathology, Molecular and Cell Based Medicine; Icahn School of Medicine at Mount Sinai

PHS Funding: NIH 1 U01 AI170074-01 *Promoting and Visualizing Immune Regulation in Transplantation*

Role on Research Project: Co-investigator

Name of the Entity in which Significant Financial Interest (SFI) is held: Trained Therapeutix Discovery

Nature of the SFI: Equity interest

Approximate dollar value of the SFI: Equity interest values are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value

162.

Date Disclosed: September 28, 2022

Investigator with FCOI: Robert Gaunt

Title: Associate Professor, Department of Physical Medicine and Rehabilitation

PHS Funding: NIH 5 U01 NS 123125-02 *Influence of task complexity and sensory feedback on cortical control of grasp force*

Role on Research Project: Co-investigator

Name of the Entity in which Significant Financial Interest (SFI) is held: Blackrock Microsystems, LLC

Nature of the SFI: Consulting

Approximate dollar value of the SFI: \$100,000 - \$149,999

163.

Date Disclosed: September 28, 2022

Investigator with FCOI: Robert Gaunt

Title: Associate Professor, Department of Physical Medicine and Rehabilitation

PHS Funding: NIH 1 R01 NS 121079-01A1 *Quantifying neural variability and learning during real world brain-computer interface use*

Role on Research Project: Co-investigator

Name of the Entity in which Significant Financial Interest (SFI) is held: Blackrock Microsystems, LLC

Nature of the SFI: Consulting

Approximate dollar value of the SFI: \$100,000 - \$149,999

164.

Date Disclosed: October 10, 2022

Investigator with FCOI: Eric Nestler

Title: Professor, Department of Neuroscience, Pharmacological Sciences, and Psychiatry; Icahn School of Medicine at Mount Sinai

PHS Funding: NIH 2 R01 DA040620-06A1 *Glial-mediated synaptic remodeling in drug addiction*

Role on Research Project: Co-investigator

Name of the Entity in which Significant Financial Interest (SFI) is held: EpiVario

Nature of the SFI: Equity interest

Approximate dollar value of the SFI: Equity interest values are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value

165.

Date Disclosed: October 13, 2022

Investigator with FCOI: Gilles Clermont

Title: Professor of Critical Care Medicine, Mathematics, Clinical and Translational Science

PHS Funding: NIH 9 R01 EB032752-08A1 *Learning alerting models for clinical care from EMR data and human knowledge*

Role on Research Project: Co- investigator of bench and human research

Name of Entity in which Significant Financial Interest (SFI) is held: NOMA AI, Inc.

Nature of the SFI: Equity interest; management position

Approximate dollar value of the SFI: Equity/management position - The interests are ones whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

166.

Date Disclosed: October 13, 2022

Investigator with FCOI: Milos Hauskrecht,

Title: Professor of Computer Science

PHS Funding: NIH 9 R01 EB032752-08A1 *Learning alerting models for clinical care from EMR data and human knowledge*

Role on Research Project: Principal investigator of bench research and co-investigator human research

Name of Entity in which Significant Financial Interest (SFI) is held: NOMA AI, Inc.

Nature of the SFI: Equity interest; management position

Approximate dollar value of the SFI: Equity/management position - The interests are ones whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

167.

Date Disclosed: November 1, 2022

Investigator with FCOI: Chen, Beibei

Title: Professor of Medicine

PHS Funding: NIH 5 R35 HL139860-05 *Systematic Investigation of Protein Ubiquitination in ARDS*

Role on Research Project: Principal investigator of bench research

Name of Entity in which Significant Financial Interest (SFI) is held: Coloma Therapeutics

Nature of the SFI: Equity interest; management position

Approximate dollar value of the SFI: Equity/management position - The interests are ones whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

168.

Date Disclosed: November 1, 2022

Investigator with FCOI: Liu, Yuan

Title: Assistant Professor, Division of Pulmonary, Allergy, and Critical Care Medicine

PHS Funding: NIH 5 R35 HL139860-05 *Systematic Investigation of Protein Ubiquitination in ARDS*

Role on Research Project: Co-investigator of bench research

Name of the Entity in which Significant Financial Interest (SFI) is held: Coloma Therapeutics

Nature of the SFI: Equity interest; management position

Approximate dollar value of the SFI: Equity/management position - The interests are ones whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

169.

Date Disclosed: November 7, 2022, 2022

Investigator with FCOI: Dario A.A. Vignali, PhD

Title: Professor and Vice Chair, Department of Immunology

PHS Funding: NIH 2 P50 CA097190-16A1 *Head and Neck Cancer SPORE*

Role on Research Project: Co-investigator of bench research

Name of the Entity in which Significant Financial Interest (SFI) is held: Bristol-Myers Squibb

Nature of the SFI: Equity interest; consulting; intellectual property rights (e.g., royalties, patents, copyrights) assigned to Johns Hopkins University/St. Jude Children's Research Hospital, Inc. and licensed to Bristol-Myers Squibb

Approximate dollar value of the SFI: Aggregate of equity interest and consulting income between \$20,000 - \$29,999; intellectual property rights between \$80,000 - \$99,999

170.

Date Disclosed: November 15, 2022

Investigator with FCOI: Greg Delgoffe, PhD

Title: Associate Professor, Department of Immunology; Director, Tumor Microenvironment Center

PHS Funding: NIH 1 R01 1A1166598-01A1 *Uncovering the metabolic underpinnings of T cell exhaustion*

Role on Research Project: Principal investigator

Name of the Entity in which Significant Financial Interest (SFI) is held: Remplir Bio, Inc.

Nature of the SFI: Equity interest; management position

Approximate dollar value of the SFI: Equity/management position - The interests are ones whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

171.

Date Disclosed: November 18, 2022

Investigator with FCOI: Marco Capogrosso, PhD

Title: Assistant Professor of Neurological Surgery

PHS Funding: NIH 1 UG3 NS123135-01A1 *Spinal Cord Stimulation to Improve Motor Function in People with Post-Stroke Hemiplegia*

Role on Research Project: Co-Investigator

Name of the Entity in which Significant Financial Interest (SFI) is held: Reach Neuro, Inc.

Nature of the SFI: Equity interest; Management position

Approximate dollar value of the SFI: The interests are ones whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

172.

Date Disclosed: November 18, 2022

Investigator with FCOI: Elvira Pirondini, PhD

Title: Assistant Professor of Physical Medicine and Rehabilitation

PHS Funding: NIH 1 UG3 NS123135-01A1 *Spinal Cord Stimulation to Improve Motor Function in People with Post-Stroke Hemiplegia*

Role on Research Project: Co-Investigator

Name of the Entity in which Significant Financial Interest (SFI) is held: Reach Neuro, Inc.

Nature of the SFI: Equity interest; Spouse management position

Approximate dollar value of the SFI: The interests are ones whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

173.

Date Disclosed: November 18, 2022

Investigator with FCOI: Peter Gerszten, MD

Title: Assistant Professor of Neurosurgery

PHS Funding: NIH 1 UG3 NS123135-01A1 *Spinal Cord Stimulation to Improve Motor Function in People with Post-Stroke Hemiplegia*

Role on Research Project: Co-Investigator

Name of the Entity in which Significant Financial Interest (SFI) is held: Reach Neuro, Inc.

Nature of the SFI: Equity interest; Management position

Approximate dollar value of the SFI: The interests are ones whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

174.

Date Disclosed: February 6, 2023

Investigator with FCOI: Marco Fazzari, PhD

Title: Research Assistant Professor of Pharmacology & Chemical Biology

PHS Funding: NIH 1 R01 HL162787-01A1 *Nitro-nitrate fatty acid derivatives as novel cGMP-dependent and cGMP independent signaling mediators*

Role on Research Project: Principal Investigator

Name of the Entity in which Significant Financial Interest (SFI) is held: Creegh Pharmaceuticals, Inc.

Nature of the SFI: Equity interest

Approximate dollar value of the SFI: The interests are ones whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

175.

Date Disclosed: February 13, 2023

Investigator with FCOI: Bruce Freeman, PhD

Title: Chair and Professor of Pharmacology & Chemical Biology

PHS Funding: NIH 1 R01 HL162787-01A1 *Nitro-nitrate fatty acid derivatives as novel cGMP-dependent and cGMP independent signaling mediators*

Role on Research Project: Co-Investigator

Name of the Entity in which Significant Financial Interest (SFI) is held: Creegh Pharmaceuticals, Inc.

Nature of the SFI: Equity interest; Management position

Approximate dollar value of the SFI: The interests are ones whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

176.

Date Disclosed: February 20, 2023

Investigator with FCOI: Leah Byrne, PhD

Title: Assistant Professor of Ophthalmology

PHS Funding: NIH 1 R01 EY033049-01A1 *Retinal-Adhesive Thermoresponsive Gel for AAV-Mediated Gene Delivery to the Outer Retina*

Role on Research Project: Co-Investigator on bench research and serving as PI of animal research

Name of the Entity in which Significant Financial Interest (SFI) is held: Avista Therapeutics

Nature of the SFI: Equity interest; Management position

Approximate dollar value of the SFI: Equity interests are ones whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value; Management position: \$100,000 - \$149,999 in a 12-month period

177.

Date Disclosed: February 20, 2023

Investigator with FCOI: Leah Byrne, PhD

Title: Assistant Professor of Ophthalmology

PHS Funding: NIH 1 UF1 MH130881-01 *Cell Type Specific AAVs to Study Reward and Cognition*

Role on Research Project: Co-Investigator on bench research and serving as PI of animal research

Name of the Entity in which Significant Financial Interest (SFI) is held: Avista Therapeutics

Nature of the SFI: Equity interest; Management position

Approximate dollar value of the SFI: Equity interests are ones whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value; Management position: \$100,000 - \$149,999 in a 12-month period

178.

Date Disclosed: March 9, 2023

Investigator with FCOI: Jose-Alain Sahel, PhD

Title: Professor and Chair of Ophthalmology

PHS Funding: NIH 1 R01 EY033049-01A1 *Retinal-Adhesive Thermoresponsive Gel for AAV-Mediated Gene Delivery to the Outer Retina*

Role on Research Project: Principal Investigator on bench research

Name of the Entity in which Significant Financial Interest (SFI) is held: Avista Therapeutics

Nature of the SFI: Equity interest; Consulting

Approximate dollar value of the SFI: Equity interests are ones whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value; Consulting: \$100,000 - \$149,999 in a 12-month period

179.

Date Disclosed: March 9, 2023

Investigator with FCOI: George Gittes, MD

Title: Professor and Chair of Pediatric Surgery and Pediatrics

PHS Funding: NIH 5 R01 DK120698-04 *Chemical Pancreatectomy for Chronic Pancreatitis and Pancreatic Cancer*

Role on Research Project: Principal investigator on bench research and serving as PI of animal research

Name of the Entity in which Significant Financial Interest (SFI) is held: Genprex

Nature of the SFI: Consulting

Approximate dollar value of the SFI: Consulting: \$20,000-\$39,999 in a 12-month period

180.

Date Disclosed: March 24, 2023

Investigator with FCOI: Louis Faló, MD

Title: Professor and Chair of Dermatology

PHS Funding: NIH 5 R01 AR079233-03 *Engineering the Skin Immune System to Induce Systemic Immune Responses*

Role on Research Project: Principal investigator on bench research and serving as PI of animal research

Name of the Entity in which Significant Financial Interest (SFI) is held: Panther Life Sciences

Nature of the SFI: Equity interest; Management position

Approximate dollar value of the SFI: Equity interest: value cannot be readily determined; Management position: value cannot be readily determined

181.

Date Disclosed: March 24, 2023

Investigator with FCOI: Louis Faló, MD

Title: Professor and Chair of Dermatology

PHS Funding: NIH 5 R01 AR079233-03 *Engineering the Skin Immune System to Induce Systemic Immune Responses*

Role on Research Project: Principal investigator on bench research and serving as PI of animal research

Name of the Entity in which Significant Financial Interest (SFI) is held: SkinJect

Nature of the SFI: Equity interest

Approximate dollar value of the SFI: Value cannot be readily determined

182.

Date Disclosed: May 5, 2023

Investigator with FCOI: Song Li, MD, PhD

Title: Professor and Chair of Dermatology

PHS Funding: NIH 1 R01 CA278608-01 Nanoparticles-mediated combination therapy for breast cancer

Role on Research Project: Principal investigator on bench research and serving as PI of animal research

Name of the Entity in which Significant Financial Interest (SFI) is held: SiRNAMed Therapeutics, Inc.

Nature of the SFI: Equity interest; Management position

Approximate dollar value of the SFI: Equity interest: value cannot be readily determined; Management position: value cannot be readily determined

183.

Date Disclosed: May 23, 2023

Investigator with FCOI: Jason Lohmueller PhD

Title: Assistant Professor, Departments of Surgery and Immunology

PHS Funding: NIH 5 R01 GM142007-02 *Conditional control of universal antigen receptor signaling*

Role on Research Project: Principal Investigator

Name of the Entity in which Significant Financial Interest (SFI) is held: Coeptis Therapeutics Holdings, Inc.

Nature of the SFI: University of Pittsburgh intellectual property rights

Approximate dollar value of the SFI: \$10,000 - \$19,999

184.

Date Disclosed: June 2, 2023

Investigator with FCOI: Stephen Badylak, DVM, PhD, MD

Title: Professor, Department of Surgery

PHS Funding: NIH 1 R01 AA030007-01 *The role of matrix-bound microvesicles in alcohol-related liver disease*

Role on Research Project: Co-Investigator

Name of the Entity in which Significant Financial Interest (SFI) is held: ECM Therapeutics, Inc.

Nature of the SFI: Equity interest; Management position

Approximate dollar value of the SFI: Equity interest: value cannot be readily determined; Management position: \$100,000 - \$149,999

185.

Date Disclosed: June 2, 2023

Investigator with FCOI: George Hussey, PhD

Title: Assistant Professor, Department of Pathology

PHS Funding: NIH 1 R01 AA030007-01 *The role of matrix-bound microvesicles in alcohol-related liver disease*

Role on Research Project: Co-Investigator

Name of the Entity in which Significant Financial Interest (SFI) is held: ECM Therapeutics, Inc.

Nature of the SFI: Equity interest; Consulting

Approximate dollar value of the SFI: Equity interest: value cannot be readily determined; Consulting: \$60,000 - \$79,999

186.

Date Disclosed: June 23, 2023

Investigator with FCOI: Aman Mahajan, MD, PhD, MBA

Title: Professor and Chair, Department of Anesthesiology and Perioperative Medicine

PHS Funding: NIH 1 R42 HL167342-01 *A non-invasive, automated platform for hemodynamic assessment of patients at risk of heart failure or pulmonary hypertension*

Role on Research Project: Principal Investigator on bench research and Co-Investigator on human subjects research

Name of the Entity in which Significant Financial Interest (SFI) is held: Sensydia Corporation

Nature of the SFI: Equity interest; Management position

Approximate dollar value of the SFI: Equity interest: value cannot be readily determined; Management position: \$40,000-\$59,999

187.

Date Disclosed: June 23, 2023

Investigator with FCOI: Samir Saba, MD

Title: Professor and Chief, Department of Medicine, Division of Cardiology

PHS Funding: NIH 1 R42 HL167342-01 *A non-invasive, automated platform for hemodynamic assessment of patients at risk of heart failure or pulmonary hypertension*

Role on Research Project: Co-Investigator

Name of the Entity in which Significant Financial Interest (SFI) is held: Sensydia Corporation

Nature of the SFI: Equity interest

Approximate dollar value of the SFI: Equity interest: value cannot be readily determined

188.

Date Disclosed: July 3, 2023

Investigator with FCOI: Robert Friedlander, MD

Title: Distinguished Professor and Chair, Department of Neurological Surgery

PHS Funding: NIH 5 UL1 TR001857-08 *University of Pittsburgh Clinical and Translational Science Institute*

Role on Research Project: Co-Investigator

Name of the Entity in which Significant Financial Interest (SFI) is held: Astria Biosciences

Nature of the SFI: Equity interest

Approximate dollar value of the SFI: Value cannot be readily determined

189.

Date Disclosed: July 3, 2023

Investigator with FCOI: Aditya (Adi) Mittal

Title: Research Fellow, Department of Neurological Surgery

PHS Funding: NIH 5 UL1 TR001857-08 *University of Pittsburgh Clinical and Translational Science Institute*

Role on Research Project: Co-Investigator

Name of the Entity in which Significant Financial Interest (SFI) is held: Astria Biosciences

Nature of the SFI: Equity interest; Management position

Approximate dollar value of the SFI: Equity interest: value cannot be readily determined; Management position: value cannot be readily determined

190.

Date Disclosed: July 3, 2023

Investigator with FCOI: Robert Dembinski

Title: Medical Student, Department of Neurological Surgery

PHS Funding: NIH 5 UL1 TR001857-08 *University of Pittsburgh Clinical and Translational Science Institute*

Role on Research Project: Co-Investigator

Name of the Entity in which Significant Financial Interest (SFI) is held: Astria Biosciences

Nature of the SFI: Equity interest; Management position

Approximate dollar value of the SFI: Equity interest: value cannot be readily determined; Management position: value cannot be readily determined

191.

Date Disclosed: July 10, 2023

Investigator with FCOI: Ali Alattar, MD

Title: Resident, Department of Neurological Surgery

PHS Funding: NIH 5 UL1 TR001857-08 *University of Pittsburgh Clinical and Translational Science Institute*

Role on Research Project: Co-Investigator

Name of the Entity in which Significant Financial Interest (SFI) is held: Astria Biosciences

Nature of the SFI: Equity interest; Management position

Approximate dollar value of the SFI: Equity interest: value cannot be readily determined; Management position: value cannot be readily determined

192.

Date Disclosed: July 12, 2023

Investigator with FCOI: Francisco J. Schopfer, PhD

Title: Professor, Department of Pharmacology and Chemical Biology

PHS Funding: NIH 5 R01 GM125944-06 *Formation and metabolism of nitrated fatty acids*

Role on Research Project: Principal Investigator

Name of the Entity in which Significant Financial Interest (SFI) is held: Furanica, Inc.

Nature of the SFI: Equity interest; Management position

Approximate dollar value of the SFI: Equity interest: value cannot be readily determined; Management position: \$20,000-\$39,999